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1.  Introduction 
 
Our immune system protects us from diseases caused by pathogenic organisms, 
foreign cells and tissues and from the development of tumors. It is a system of highly 
complex processes, specialized cells and tissues. Disorders in the immune system can 
cause diseases. The so called immunodeficiency diseases are characterized by a less 
active or inactive immune system. This is causing the host to be especially vulnerable 
to infections. Autoimmunity on the other side is characterized by an overactive 
immune system, recognizing normal tissue and proteins as non-self. This is causing 
the immune system to destruct healthy own cells and tissues. Hypersensitivity 
diseases are damaging reactions of a normal immune system, which require a prior 
sensitization of the host.  
 
The healthy immune system of vertebrates acts in a very specific way. Its activity is 
inducible and can be adapted in order to ensure highest efficiency. In general the 
network can be divided into two main parts, the innate and the adaptive immunity. 
The innate immune system is the evolutionary older part and the so called first line 
defense. It is a fast but relatively unspecific response to invading pathogens. This arm 
of the immune system does not have a memory and can not adapt and be more 
efficient upon second-time encounter of the same antigen. The main components are 
the surface barriers, the complement and immune cells like phagocytes and natural 
killer cells. These are readily present also before the onset of an infection. The 
response of the adaptive immune system is dependent on highly specific antigen 
receptors expressed by the major players, the B and T lymphocytes. Upon activation, 
the antigen specific cells have to undergo clonal expansion, causing the typical delay 
in the onset of an adaptive response. Another major difference is the generation of 
memory, allowing the adaptive immune system to remember pathogens and to react 
stronger and more efficiently upon a second encounter. 
 
Major histocompatibility complex (MHC) molecules play a central role in the cell 
mediated immune response. On the surface of vertebrate, nucleated cells these 
membrane spanning proteins display self and non-self peptide antigens to T 
lymphocytes. There are two major classes of MHC molecules. MHC class I molecules 
 7
are expressed on nearly all nucleated cells. They mainly present peptides produced in 
the cytosol to cytotoxic CD8+ T cells. MHC class II proteins are exclusively 
expressed by professional antigen presenting cells (APCs). These cells mainly display 
peptides from internalized and degraded antigens in complex with MHC class II 
molecules on their cell surface. In humans MHC proteins are called HLA (human 
leukocyte antigen) and we differentiate three major class II isotypes: HLA-DP, -DQ 
and -DR.  
 
Autoimmune and hypersensitivity disorders are usually multifactorial diseases with 
involvement of multiple genetic loci and environmental factors. For many of such 
diseases, genes of the HLA gene complex are strongest genetic components, and these 
diseases display strong associations with certain HLA variants (Horton et al. 2004). 
While the major predisposing genetic factors are well described for most autoimmune 
diseases, the environmental factors and mechanisms causing disease are often 
unknown. A well studied exception is celiac disease (CD), where both the major 
environmental and the major genetic predisposing factor are known. During the last 
years CD has become a valuable model disorder, helping us to understand other 
complex HLA associated diseases. But despite the huge advances which were made in 
understanding the complex pathogenesis of CD, no specific treatment supplementing 
the strict gluten free diet is available for patients. However, one of the most 
interesting targets for a novel CD treatment is the disease associated HLA-DQ2.5 
(DQA1*0501, DQB1*0201) molecule. 
 
1.1. MHC class II
MHC class II molecules are membrane bound -dimeric glycoproteins, expressed on 
the surface of professional APCs. The three main types of professional APCs are 
dendritic cells, B cells and macrophages. As major players of the adaptive immune 
system they present peptide antigens for recognition by CD4+ T cells (Babbitt et al. 
1985). These peptides derive mainly from the exogenous pathway. By this pathway 
extracellular proteins or peptides are internalized into vesicles and transported through 
the endocytic compartment. Subsequently they are degraded by proteases deriving 
from lysozymic vesicles. The antigen fragments are then transported into the MHC 
class II compartment (MIIC), where MHC class II peptide complexes are formed. All 
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MHC class II molecules are assembled in the ER and subsequently chaperoned into 
the MIIC by invariant chain (Ii) in form of a nonameric complex (Roche et al. 1991). 
Ii is interacting with the peptide binding groove and prevents premature peptide 
binding (Cresswell 1996). Enzymes in the MIIC cleave Ii, but leave a peptide (CLIP 
peptide) bound to the peptide binding groove. This peptide will finally be exchanged 
for an antigen derived peptide with higher affinity (Cresswell 1994), in a process 
controlled and catalyzed by a specialized non-classic HLA protein, HLA-DM (Denzin 
and Cresswell 1995). 
 
1.1.1. The MHC:peptide complex 
All MHC class II molecules consist of two glycoprotein subunits. The membrane 
distal parts of both extracellular domains (1 and 1) are forming the peptide binding 
groove as an interchain dimer. The floor of the binding groove is formed by eight 
strands of antiparallel -sheets (each chain is contributing 4 strands), the walls by two 
-helices, one from each domain (Brown et al. 1993). The binding region of both the 
- and -chain, is rich in polymorphic residues (Stern et al. 1994). The deep groove 
which is formed between the two helices is open at both sides and allows to stably 
bind and present peptides with variable length and a relatively broad diversity (Brown 
et al. 1993;Madden 1995). Peptides bound to MHC adopt an extended, polyproline 
type II conformation (Jardetzky et al. 1996;Stern et al. 1994). The MHC:peptide 
complex is stabilized by hydrogen bonds mainly between conserved residues of the 
MHC class II molecule and the peptide backbone. Additionally, the polymorphic 
residues within the peptide binding groove form pockets, which can accommodate the 
side chains of the amino acid residues in positions P1, P4, P6, P7 and P9 of the 
peptide, the so called anchor positions. The peptide residues in the non-anchor 
positions P2, P3, P5 and P8 can be recognized by T-cell receptors (TCR). Together 
with the MHC surface, they form the T-cell recognition site (Stern et al. 1994). The 
stability of the MHC:peptide complex and especially the three-dimensional structure 
of the T-cell binding surface (formed by the two -helices as well as the bound 
peptide) define the T-cell response. T cells are highly specific and therefore even 
small changes in the structure of the bound peptide can result in a drastic change of 
the T-cell response (Bertoletti et al. 1994;Bielekova and Martin 2001).  
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1.1.2. The peptide binding motif of HLA-DQ2.5  
The first peptide elution experiments with HLA-DQ2.5 were performed 14 years ago 
and led, in combination with binding experiments using truncated and substituted 
derivates, to the characterization of the peptide binding motif of this molecule (Table 
1). HLA-DQ2.5 can accommodate negative charges in almost all positions of the 
peptide binding frame (Stepniak et al. 2008), but shows strong preference for 
glutamate only in positions P4, P6 and P7. The ability to accommodate many negative 
charges together with the preference for bulky hydrophobic residues in positions P1 
and P9, are the unique characteristics of the HLA-DQ2.5 molecule (Johansen et al. 
1996a;van de Wal et al. 1996;Vartdal et al. 1996).  
 
Table 1: Characteristic features of typical amino acid residues and preferred amino 
acids identified in important positions of the HLA-DQ2.5 peptide binding site. 
Peptide binding 
register position Characteristic features 
Preferred
amino acids Reference 
P1
anchor position -bulky hydrophobic residues 
1
P, V
W, F, Y, I, V, L 
I, L 
(Stepniak et al. 2008) 
(Vartdal et al. 1996)  
(van de Wal et al. 1996) 
P2 -hydrogen bond involving 
peptide main chain amide 2
P4
anchor position 
-negative charges 1
-hydrogen bond involving 
peptide main chain amide 2
D, E 
D, E, L, V, I 
D, E, A 
(Stepniak et al. 2008) 
(Vartdal et al. 1996)  
(van de Wal et al. 1996) 
P6
anchor position 
-negative charges 4,5
-hydrogen bond involving   
peptide main chain amide 2
D, E, A 
D, E, P 
P, A 
(Stepniak et al. 2008) 
(Vartdal et al. 1996) 
(van de Wal et al. 1996) 
P7
anchor position -negative charges 
1
D, E 
D, E 
D, E, W, A
(Stepniak et al. 2008) 
(Vartdal et al. 1996)van 
(van de Wal et al. 1996) 
P8 P (Stepniak et al. 2008) 
P9
anchor position 
-bulky hydrophobic residues 1,3
-negative charges 4
-hydrogen bond involving 
peptide main chain amide 2
F, L, E 
W, F, Y, I, L, V, M 
W, Y, A,   
(Stepniak et al. 2008) 
(Vartdal et al. 1996) 
(van de Wal et al. 1996) 
1 (Johansen et al. 1996b), 2 (Bergseng et al. 2005), 3 (Quarsten et al. 1998), 4 (Stepniak 
et al. 2008), 5 (Vartdal et al. 1996) 
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 The X-ray crystal structure of HLA-DQ2.5 with the DQ2--I-gliadin epitope 
QLQPFPQPELPY has been solved with a resolution of 2.2 Å (Kim et al. 2004). It 
demonstrated that side chains of residues at positions P4, P6 and P7 can dock into the 
corresponding binding pockets of HLA-DQ2.5. Further it proved that glutamate in P6 
is a very important anchor residue due to two principles: by participating in a wide 
spanning hydrogen bonding network and by charge complementation to the Lys-71 
residue of HLA-DQ2.5. In many gluten derived antigens there are negatively charged 
amino acids in position P6, but also in positions P4 and/or P7. The crystal structure 
showed that these charges are complemented by the positive charges of Arg-70 or 
Lys-71.  
 
Interestingly, most of the binding energy in the MHC:peptide complexes is calculated 
to originate from the hydrogen bonding network (Stern et al. 1994). Gluten derived 
epitopes, however, contain many proline residues - the only proteinogenic amino acid 
unable to donate a hydrogen bond due to its tertiary amide nitrogen. The 
immunodominant DQ2--I-gliadin epitope for example contains four proline residues. 
Again, the crystal structure showed how this molecule can accommodate these many 
proline residues and still maintain a strong hydrogen bonding network (illustrated in 
Fig.1). If proline is accepted in positions P1, P3, P5 and P8, the binding energy from 
main chain hydrogen bonding interactions in positions P-2, P-1, P2, P4, P6, P7 and P9 
is retained. Interestingly, no other HLA class II molecule appears to be able to bind 
proline in position P1. In HLA-DQ2.5 this seems to be possible due to a deletion 
mutation of the 53 residue, causing the loss of the typical hydrogen bond which is 
reported for many other MHC class II molecules in this position (Ghosh et al. 
1995;Smith et al. 1998;Stern et al. 1994).  
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P1
P3 P5 P8
 
Figure 1: Overview over the complex hydrogen bonding network between conserved 
and polymorphic residues of HLA-DQ2.5 and the backbone amide nitrogen (-NH) and 
carbonyl oxygen (–C=O) of the -I-gliadin peptide. The five pockets of HLA-DQ2.5 
are indicated by grey half circles and backbone amide hydrogen bonds are shown by 
stars (Bergseng et al. 2005;Kim et al. 2004;Nelson and Fremont 1999). 
 
High affinity binders are composed of favorable amino acids residues in all nine 
positions of the peptide binding frame. Generally, peptides with high affinity to HLA-
DQ2.5 contain several negative charges (preferably in positions P4, P6 and P7), bulky 
hydrophobic residues in positions P1 and P9, and amino acids participating in a 
hydrogen bonding network in positions P2, P4, P6, P7 and P9. Important as well are 
additional hydrogen bonds between HLA-DQ2.5 and the peptide main chain outside 
of the P1-P9 core binding region (Fig. 1). Binding affinities usually increase when 
further amino acids are added N- and C-terminally to the core binding region (Bartnes 
et al. 1999;Kim et al. 2004). 
 
1.1.3. Gluten derived peptides presented by HLA-DQ2.5 
Wheat gluten and related grain storage proteins from rye and barley are the harmful 
molecules in CD. Gluten is a complex protein composite of gliadins and glutenins. 
The gliadins can be grouped into -, -, and -gliadins (Wieser et al. 1987), a 
nomenclature based primary on their sequence characteristics and on their 
electrophoretic mobility at low pH. Glutenins are grouped into high- and low 
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molecular weight subunits. Both subunits contain intrachain disulfide bonds and are 
poorly soluble in water and other aqueous solutions. In addition, the glutenins contain 
interchain disulfide bonds. Gluten proteins are unusually rich in proline (~15%) and 
glutamine (~30%). Immunogenic epitopes which are typically presented by HLA-
DQ2.5 are often found to cluster in proline-rich regions. There are several probable 
reasons for this epitope clustering. An important reason is that proline is protecting 
larger fragments from complete digestion. The human intestine is lacking enzymes 
feasible to degrade peptides with high proline content, the so called endoprolyl 
peptidases. As a consequences, large proline rich peptides survive digestion in the 
small intestine, and these fragments are shown to cross the mucosal surface into the 
lamina propria (Hausch et al. 2002). In individuals with CD, patrolling APCs with 
HLA-DQ2.5 and/or HLA-DQ8 on their surface will recognize special epitopes from 
proline rich regions and bind and present them in complex with HLA to T cells. It is 
also shown that gluten derived epitopes with many proline residues adopt a left-
handed polyproline type II (PPII) helical conformation. This might support binding to 
HLA-DQ2.5, as HLA molecules are shown to cause a PPII conformation in their 
bound ligands (Jardetzky et al. 1996;Parrot et al. 2002).  
 
I described earlier that HLA-DQ2.5 prefers negatively charged residues in almost all 
positions of the peptide binding frame. Natural ligands as well as gluten derived 
epitopes carry many negative charges. Gluten however is not rich in glutamate, but in 
non-charged glutamine residues. This paradox was solved when the enzyme tissue 
transglutaminase (TG2) was observed to perform deamidation of specific glutamine 
residues in gluten derived epitopes (Molberg et al. 1998). This deamidation is 
introducing negative charges which in turn increase the peptide binding affinity to 
HLA-DQ2.5 (Fleckenstein et al. 2002;Qiao et al. 2005). The glutamate residues 
which are targeted by TG2 are almost always in position P-2 of a proline residue. This 
specific deamidation is another probable reason why epitopes cluster in proline-rich 
sequences. And finally, it is observed that multiple binding sites can enhance the 
binding affinity of a peptide compared to single binding sites (Sette et al. 1990). The 
highly immunogenic 33mer gliadin peptide for example is shown to be proteolytically 
stable and contains multiple copies of three different T-cell epitopes and 13 proline 
residues (Shan et al. 2002). 
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1.1.4. Detergent-solubilized and water soluble MHC class II molecules  
Detergent-solubilized MHC class II molecules can be purified from homozygous 
Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines. These molecules 
are widely used to elucidate peptide binding properties by elution and identification of 
natural bound ligands and in peptide binding assays to analyze binding affinities of 
synthetic peptides (Falk et al. 1994;Jardetzky et al. 1990;Krieger et al. 
1991;O'Sullivan et al. 1990;Rammensee et al. 1995). Also the binding motif of HLA-
DQ2.5 was characterized by using such detergent-solubilized molecules (Johansen et 
al. 1994;van de Wal et al. 1996;Vartdal et al. 1996).  
 
Water soluble MHC molecules were made to study interactions between MHC, 
peptide and TCR in a detergent free environment (Wettstein et al. 1991) and in order 
to solve the crystal structure of these complexes (Kozono et al. 1994;Stern et al. 
1994). Today, these molecules are widely used in tetramer technology, for the 
identification, quantification and isolation of specific T cells. 
 
Expression of MHC class II molecules in insect cells became a commonly used 
method for the production of recombinant molecules (De Wall et al. 2006;Stern and 
Wiley 1992;Wallny et al. 1995). Initially, HLA-DR1 and other MHC class II 
molecules were expressed without a covalently tethered peptide as so called “empty” 
class II molecules (Stern and Wiley 1992). The expression of recombinant molecules 
with a high affinity ligand covalently tethered to the N-terminus of the -chain 
(Crawford et al. 1998) however gave improved expression and more stable molecules. 
Therefore this strategy developed as a preferred expression modality. In our hands the 
“empty” HLA-DQ2.5 molecules, which we expressed in a Drosophila melanogaster 
S2 cell line, gave unusually high protein quantity. However, these molecules were not 
empty, instead an insect cell derived protein was stably bound to the peptide binding 
site (Jüse et al. 2009).  
 
1.2. Celiac disease  
CD is a gluten induced, autoimmune-like inflammatory disorder of the small intestine 
and therefore often referred to as gluten sensitive enteropathy. As for many diseases 
with autoimmune characteristics, CD is associated with certain HLA molecules. Over 
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90% of the CD patients express HLA-DQ2.5 and most of the remaining express HLA-
DQ8. Gluten from wheat seeds and related storage proteins in seeds from barley and 
rye are known as the environmental triggers of CD (Dicke et al. 1953;Trier 
1991;Wieser 1995;Wiesner et al. 2008). It has been shown that peptides deriving from 
both subgroups of gluten, the gliadins and glutenins, are toxic for CD patients 
(Ciclitira et al. 1984;Dewar et al. 2006;Lundin et al. 1993;Lundin et al. 1994;Molberg 
et al. 1997;Vader et al. 2002). Upon ingestion of these proteins, young individuals 
with CD often present with typical symptoms like chronic diarrhea, abdominal pain, 
malabsorption and failure to thrive (Maki and Collin 1997). In adult patients, 
symptoms are often less typical and may include weight loss and extra intestinal 
symptoms like neurological and behavioral disorders (Fasano and Catassi 2001). CD 
is diagnosed in about 0,5-1% of the Western civilization (Dube et al. 2005;Maki et al. 
2003). Diagnosis is especially difficult in adults, due to the often more unspecific 
symptoms, silent CD or disease latency. Therefore, the actual CD prevalence in the 
population might be even higher then calculated (Fasano and Catassi 2001;Maki and 
Collin 1997). The only successful treatment today is a life-long total exclusion of 
gluten and related proteins from the diet. This treatment has a very good benefit-risk 
ratio, however, due to poor diet compliance or silent disease the risk increases for 
developing other autoimmune diseases (Cosnes et al. 2008;Ventura et al. 1999), 
diverse neurological symptoms (Cooke and Smith 1966;Zelnik et al. 2004), infertility 
(Sher and Mayberry 1994), osteoporosis (Molteni et al. 1990) and intestinal 
lymphoma (Holmes et al. 1989;Maki and Collin 1997). Therefore, there is an unmet 
need for alternative treatments. 
 
1.2.1. Pathogenesis 
The pathogenesis of CD is a complex interplay of the innate and adaptive immune 
system, which in CD patients become both activated upon gluten ingestion (Jabri and 
Sollid 2009). As described above, especially the proline rich fragments of gluten 
proteins survive gastrointestinal digestion and are able to cross the mucosal 
epithelium into the lamina propria. Eventually they get enzymatically deamidated by 
TG2 (most epitopes are dependent on this conversion), a modification which is 
introducing negative charges. APCs in the lamina propria can bind the now negatively 
charged epitopes and present them in complex with HLA-DQ2.5 or HLA-DQ8 on 
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their surface. These complexes are recognized by specific gluten reactive CD4+ T 
cells, which upon recognition will become activated (Molberg et al. 1998;Qiao et al. 
2009). This activation step can be modulated by a secondary signal which is 
especially important for successful activation of naïve T cells. A secondary signal is 
provided by a variety of co-stimulating molecules such as CD28, CTLA-4 and 
CD40L on the T cell, as they interact with their counterparts on the APC surface. 
Following activation, naïve CD4+ T cells can differentiate into different functional 
subsets. The cytokine environment, the type of involved co-stimulating molecules and 
the dose of stimulation determine the kind of T-cell subset. The Th1 subset, which is 
associated with inflammation and tissue damage in autoimmune diseases, is the major 
subset found in CD (Nilsen et al. 1995). Typical for gluten reactive Th1 cells is the 
huge production of IFN- (Ben-Horin et al. 2006;Nilsen et al. 1998). As T-helpers 
these cells promote B-cell development into plasma cells which produce IgG and IgA 
antibodies directed against (deamidated) gluten and TG2 (Dieterich et al. 1997;Lerner 
et al. 1994;Sollid et al. 1997).  
 
Another T-cell population typically increased in the celiac lesion is the intraepithelial 
lymphocytes (IEL), mostly of the TCR +CD8+CD4- cytotoxic T-cell subtype. These 
T cells belong to the innate immune system. In biopsies from CD patients, up to 70-80 
IEL are found per 100 duodenal epithelial cells. In patients on a GFD, a decrease in 
the number of IEL is only partly seen (Ferguson and Murray 1971). Therefore, IEL 
have become an indicator for CD. Cytotoxic IEL are also found to express the 
heterodimeric CD94/NKG2 receptors on their surface which are reported to have 
inhibitory or activating functions. In the healthy state, CD94/NKG2A+ TCR+ IEL 
produce the transforming growth factor (TGF)- when they interact with their ligand 
HLA-E on the surface of cells of the mucosal epithelium (Bhagat et al. 2008). This is 
thought to suppress the activation of cytotoxic IEL. A massive IL-15 production by 
stressed epithelial cells however is blocking the TGF- effect and in turn activates an 
up-regulation of a different NK receptor, CD94/NKG2D. This receptor allows the 
recognition of stressed enterocytes expressing MICA (Roberts et al. 2001). Upon 
recognition, the IEL is directly cytotoxic to the MICA expressing stressed epithelial 
cells (Hüe et al. 2004;Jabri and Sollid 2006;Meresse et al. 2006). Typically, cytolysis 
is performed in a TCR independent manner and without inducing IEL proliferation or 
cytokine production (Hüe et al. 2004;Maiuri et al. 2000;Maiuri et al. 2003). The 
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gliadin induced process of tissue damage is dependent on the IL-15 production and 
can be inhibited by antibodies neutralizing IL-15 (Maiuri et al. 2003). It is further 
proposed that IL-15 production is directly induced by gliadin or by the gliadin-derived 
peptide p31-49 (Hüe et al. 2004).  
 
 
Figure 2: The pathogenesis of CD. In the gastrointestinal tract (GT), gluten is broken 
down to peptides. Proline rich regions (orange triangles) survive digestion and cross 
through the mucosal epithelium (ME) into the lamina propria (LP). The enzyme 
transglutaminase 2 (TG2) is introducing negative charges in certain positions (insert 
A). Stressed ME cells up-regulate HLA-E expression. Recognition by NKG2C on the 
surface of intra epithelial lymphocytes (IEL) triggers tissue damage, INF- 
production and IEL proliferation (insert B). Also recognition of MICA, expressed on 
the surface of stressed ME by NKG2D, triggers tissue damage (insert C). Gluten up-
regulates both, the expression of MICA and NKG2D molecules. In the LP, negatively 
charged, proline rich gluten derived peptides are encountered by antigen presenting 
cells (APCs) which bind and present them in complex with HLA-DQ2.5 molecules to 
specific CD4+ T cells (insert D). This interaction will trigger T-cell activation and 
IFN- production. Further abbreviations: brush border (BB), villus (V), crypt (C). 
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At the same time, HLA-E molecules on epithelial cells are reported to be strongly up-
regulated in untreated CD, which as well might be a stress-induced reaction (Perera et 
al. 2007). It is speculated that this reaction may be a consequence to IFN- release by 
IEL and CD4+ T cells (Guy-Grand et al. 1998;Jabri et al. 2000;Meresse et al. 2006). 
CD94/NKG2C positive IEL might recognize the up-regulated HLA-E and initiate 
further IFN- secretion, proliferation and tissue damage (Meresse et al. 2009). 
 
1.2.2. Clinical diagnosis 
For a defined diagnosis of CD, it is necessary to analyze a biopsy of the small 
intestine. Typical biopsy findings for an active CD are blunting of the villi, crypt cell 
hyperplasia and lymphocyte infiltrations into both the epithelium and the lamina 
propria. Before taking a biopsy however, a blood sample is often drawn to measure 
the highly specific, gluten-dependent IgA and IgG autoantibodies to TG2. Only CD 
patients with active disease, not healthy controls nor CD patients on a gluten free diet, 
have anti-TG2 IgA and IgG autoantibodies in their blood (Dieterich et al. 
1998;Fasano and Catassi 2001). When a CD patient starts a strict gluten free diet, the 
anti-TG2 antibody titer drops, but the anti-TG2 antibodies reappear quickly upon 
gluten challenge. The intestinal villous atrophy and the signs of a flat mucosa take a 
lot more time to restore, up to several months or even years. The histological 
alterations during this progress are graded by the Marsh criteria, a scale ranging from 
Marsh III (complete villous atrophy) to Marsh 0 (normal mucosa) (Marsh et al. 1968). 
The original classification by Marsh has been partly modified later (Oberhuber et al. 
1999).  
 
1.2.3. Genetics 
As 90-95% of the CD patients express HLA-DQ2.5 (DQA1*0501, DQB1*0201), 
there is no doubt that this HLA molecule is the major genetic risk factor (Sollid et al. 
1989). Patients not expressing HLA-DQ2.5 are mostly HLA-DQ8 (DQA1*0301, 
DQB1*0302) positive (Spurkland et al. 1992). HLA-DQ2.2 (DQA1*0201, 
DQB1*0202) is not a risk factor and only a few HLA-DQ2.2 positive patients, most 
of these being homozygous, have been identified among the rare non-DQ2.5, non-
DQ8 CD patients (Karell et al. 2003;Sollid and Thorsby 1993). HLA-DQ2.5 and 
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HLA-DQ2.2 are highly homologous and share almost identical peptide binding 
motifs. HLA-DQ2.2 however has been shown to have an increased off-rate for 
immunogenic gliadin peptides compared to HLA-DQ2.5, which might prevent 
successful presentation to specific T cells in the gut associated lymphoid tissue 
(Fallang et al. 2009). The increased stability of the HLA-DQ2.5:peptide complex is 
caused by an additional hydrogen bond from the polymorphic residue Tyr-22 to the 
peptide main chain. In HLA-DQ2.2 this tyrosine residue is replaced by a 
phenylalanine (Phe-22) which is unable to donate this hydrogen bond. 
 
HLA-DQ2.5 is encoded in cis (DR3-DQ2) or trans (DR7-DQ2, DR5-DQ7) (Sollid et 
al. 1989). Interestingly, the DR3-DQ2 haplotype is found to be associated with many 
different autoimmune disorders besides CD (type 1 diabetes, lupus, Graves’ disease) 
(Price et al. 1999;Thorsby and Lie 2005). 
 
HLA-DQ2.5 alone does however not sufficiently explain disease predisposition as 
also 25% of the healthy individuals express HLA-DQ2.5 (Sollid and Thorsby 1993). 
Also the difference between the concordance rate of monozygotic twins (70-75%) 
(Nistico et al. 2006) and the concordance rate of HLA-identical dizygotic twins (30%) 
argues for additional genetic factors (Greco et al. 2002). It has been calculated that 
HLA genes account for about 40-50% of the genetic predisposition (Meresse et al. 
2009;Sollid and Lie 2005). But what are these additional contributing genes? A 
number of studies mapping non-HLA genes for CD association, thereof several 
genome-wide association and follow-up studies, pointed out a number of possible 
candidate genes, most of them with immune function (Dubois et al. 2010;Greco et al. 
2001;Hunt et al. 2008;van Belzen et al. 2003;van Heel et al. 2005;van Heel et al. 
2007). However, no additional high risk non-HLA gene could be identified so far. 
 
1.2.4. Treatment possibilities today and in the future 
The only treatment option today is the total exclusion of gluten and related proteins 
from the diet. This is for many patients a difficult task, as gluten is widely used by the 
food industry and potentially present in every processed food product if not declared 
as “gluten free”. Gluten free products are available, but usually these are more 
expensive, and often they are not as palatable as the gluten containing products. It is 
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estimated that even of the diagnosed CD patients only 40-80% comply to a gluten free 
diet (Högberg et al. 2003;Leffler et al. 2008). Incompliant CD patients and individuals 
with silent and therefore undiagnosed disease are shown to have an increased risk to 
develop CD associated diseases (Corrao et al. 2001;Fasano and Catassi 2001).  
 
Several new treatment strategies are currently under investigation. These belong 
mainly into two different classes; the modification of gluten and the specific 
interaction with the immune response. New wheat strains with low or absent toxic 
gluten proteins could be engineered, or different plant cultivars, containing storage 
proteins with similar properties, but without antigenic epitopes, could be used as a 
wheat substitute (Frisoni et al. 1995;Molberg et al. 2005;Spaenij-Dekking et al. 
2005b;Spaenij-Dekking et al. 2005a). Yet, it has been a challenge to engineer 
modified wheat due to the large numbers of epitopes in gluten and similar proteins. 
Another strategy is the use of specific enzymes able to cleave proline rich epitopes. 
These could be supplemented to the gluten containing normal diet. Different 
endopeptidases have been described. Prolyl-endopeptidase (PEP) together with 
cysteine endoprotease (Gass et al. 2007;Gass and Khosla 2007;Shan et al. 2002;Siegel 
et al. 2006;Siegel et al. 2007) and the PEP from aspergillus niger (AN-PEP) (Stepniak 
et al. 2006) are currently tested in clinical trials. An alternative to this is the pre-
treatment of gluten containing food with bacteria derived peptidases (Di Cagno et al. 
2004). Blocking TG2 would prevent the introduction of negative charges into 
immunogenic gluten epitopes (Siegel and Khosla 2007). There are, however, gluten 
epitopes known which do not require deamidation (Dewar et al. 2006;Vader et al. 
2002) and secondly TG2 has diverse biological roles which in parts remain unknown. 
Recently, a polymeric binder with gluten sequestering ability was presented (Pinier et 
al. 2009). This polymer aims to retain gluten and to prevent the genesis of smaller 
fragments which could cross the mucosal epithelium. A novel zonulin inhibitor 
(AT1001) has been developed and tested in clinical trials to reduce the gluten induced 
epithelial barrier dysfunction (also called “leaky gut”) (Paterson et al. 2007). A tight 
epithelium is thought to decrease gluten epitope exposure in the lamina propria. 
AT1001 was found to be well tolerated and it could improve the gastrointestinal 
symptoms in CD patients. Silencing of gluten specific T cells by altered peptide 
ligands (de Haan et al. 2002;de Haan et al. 2005;Sloan-Lancaster and Allen 1996) or 
soluble HLA-DQ2:peptide complexes has been tested successfully for different 
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epitopes, however, a therapy with such complexes is difficult due to the polyclonal 
nature of T cells recognizing the same antigen. An additional limiting factor for 
peptide vaccination is the large number of epitopes (dominant and infrequent) and the 
requirement of tolerance induction to all of them. However, the first clinical trials are 
expected to start soon (Sollid and Lundin 2009). A more exotic strategy, currently in 
clinical trials, is the use of an intestinal hookworm to modulate the type of the 
immune response (Reddy and Fried 2009). Cytokine therapy is widely used to treat 
different autoimmune diseases. However, due to the typical side effects of such 
therapies and a low acceptance for side effects in CD treatment (due to that CD is not 
life threatening and GFD as a safe and effective treatment is available), none of the 
known cytokine therapy options are of interest.  
 
After all, due to a strong HLA-DQ2.5 association (over 90% of the CD patients 
express HLA-DQ2.5 (DQA1*0501, DQB1*0201)), this molecule is likely the most 
interesting target for the development of a specific treatment for CD and other HLA-
DQ2.5 associated diseases. 
 
1.2.5. Blocking presentation and/or recognition of gluten derived peptides 
Peptides or peptide-like molecules (peptidomimetics) with high affinity to HLA-
DQ2.5 could be used to interfere with the presentation of gluten derived immunogenic 
peptides. So far, the most promising approaches for blocking the HLA-DQ2.5 
mediated presentation of gluten derived antigens is the use of cyclic and dimeric 
gluten peptides (Xia et al. 2007), or the introduction of a large, chemically modified 
side chain into gluten epitopes (Kapoerchan et al. 2008). However, the efficacy of the 
blockers tested so far in in vitro T-cell assays is limited, probably due to insufficient 
affinity of the blockers to HLA-DQ2.5. In order to further develop this approach, the 
binding affinity of a HLA-DQ2.5 blocker has to be several orders of magnitude higher 
than the affinities of gluten derived antigens. In addition, blockers used for CD 
treatment in humans should fulfill several criteria. These substances should be safe, 
inexpensive, administered orally and should not introduce a potential risk for T-cell 
sensitization. 
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2. Aims of this study 
 
The major aim of my PhD project was to study peptide binding to HLA-DQ2.5 by 
means of peptide library based methods. The main focus herein was to establish a 
novel peptide library based method using recombinant, water soluble HLA-DQ2.5 
molecules and soluble complex peptide libraries. 
The specific aims towards that goal were:  
I. Design and synthesis of different soluble, synthetic peptide libraries.  
II. Production of suitable soluble, recombinant HLA-DQ2.5 molecules. 
III. Establishment of a method to isolate high affinity HLA-DQ2.5 binders from 
complex peptide mixtures. 
IV. Identification of the isolated high affinity peptides by tandem mass spectrometry 
and bioinformatics tools. 
 
With this novel peptide library approach, we can select for peptides with the highest 
HLA-DQ2.5 affinity from complex mixtures of synthetic peptides. For blocker 
development, also modified non-natural amino acids could be incorporated within 
these peptide libraries. 
 
In a different approach, we used a positional scanning peptide library and designed 
high affinity binders by combining only favourable amino acids in each position of 
the binding frame. The sequence with highest HLA-DQ2.5 affinity from these 
experiments is an interesting lead compound for the development of HLA-DQ2.5 
blockers.  
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3. Summary of the papers
 
Paper 1:  
Soluble HLA-DQ2 expressed in S2 cells copurifies with a high affinity insect cell 
derived protein 
Ulrike Jüse, Burkhard Fleckenstein, Elin Bergseng, Ludvig M. Sollid 
Immunogenetics 2009 Feb;61(2):81-9 
 
In this paper we characterize the interaction between the recombinant soluble HLA-
DQ2.5 (sDQ2) molecule and the Drosophila melanogaster derived protein DCB-45. 
This work was motivated by the stable complex formation and our interest in the 
development of reagents which inhibit HLA-DQ2.5 peptide binding. 
 
Paper 2:  
Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 
using a positional scanning peptide library 
Ulrike Jüse, Yvonne van de Wal, Frits Koning, Ludvig M. Sollid, Burkhard 
Fleckenstein 
Hum Immunol. 2010 May;71(5):475-81 
 
A positional scanning peptide library approach was used to create high affinity 
binders to HLA-DQ2.5. The peptide with highest affinity bound 50 fold stronger than 
the immunodominant DQ2--I-gliadin epitope and could serve as a lead compound in 
HLA-DQ2.5 blocker development.  
Paper 3 - manuscript 
Assessing high affinity binding to HLA-DQ2.5 by a novel library-based approach
Ulrike Jüse, Magnus Arntzen, Peter Højrup, Burkhard Fleckenstein and Ludvig M. 
Sollid 
Manuscript (submitted to Bioorganic & Medical Chemistry, 03/2010) 
 
In this manuscript we describe a novel peptide library based method which can be 
used to identify optimal binders for HLA class II molecules. In short, complex 
 23
synthetic peptide libraries were incubated with recombinant soluble HLA-DQ2.5 
molecules. Selected library peptides were eluted and analyzed by tandem mass 
spectrometry online coupled to a nano-liquid chromatography. Subsequently, peptide 
sequences were identified using the Mascot search engine and manual evaluation. 
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4. Methodological considerations 
4.1. Peptide library approach 
 
In my PhD project we have developed a novel peptide library based method, using 
soluble complex peptide libraries with one or several randomized positions (X) and 
soluble recombinant HLA-DQ2.5 molecules (sDQ2). Figure 3 is illustrating 
schematically a peptide library with 6X positions which is interacting with the HLA-
DQ2.5 binding groove.  
 
 
  
 
 
Figure 3: Schematic representation of a peptide library which is interacting with the 
peptide binding groove of HLA-DQ2.5. The residues in the positions P1, P4, P6, P7 
and P9 can interact as anchors with the pockets of the binding site. The residues in 
the positions P2, P3, P5 and P8 are solvent exposed. X is symbolizing dedicated 
positions in which an equimolar representation of 2-13 selected amino acids was 
chosen (the composition in the X positions is defined in table 2).  
 
By incubating sDQ2 with a large excess of a complex peptide mixture, we aimed to 
create an environment where only the best binders are able to compete for limited 
sDQ2 binding sites. Peptides bound to sDQ2 can then be isolated by preparative size 
exclusion chromatography and subsequently analyzed by LC-MS/MS. In the peptide 
libraries the sequence length, the alignment of binding registers, and the numbers and 
composition of randomized positions can be chosen and non-natural amino acids can 
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be included. Peptide libraries with many randomized positions are highly complex 
and can be used for the identification of optimal binders. Libraries which contain a 
single randomized position can be used to study the effect of single residue 
substitution.  
 
Each of our peptide libraries are composed of randomized (fully randomized or 
dedicated) and defined positions (Table 2).  
 
Table 2: Peptide library formats used for the identification of high affinity binders. 
Amino acids are given in the one letter code. X in the libraries I-IV encodes an 
equimolar mixture of all natural amino acids, except for cysteine. In the libraries V-
VIII, X represents a dedicated position with a composition as listed. The position of 
each amino acid in the peptide binding frame is indicated by the subscribed number. 
peptide binding register 
I G-G- F1-A2-P3-E4-K5-E6-E7-P8-X9- R-NH2
II G-G- X1-A2-P3-E4-K5-E6-E7-P8-F9- R-NH2
III G-G- X1-A2-P3-E4-K5-E6-E7-P8-X9- R-NH2
IV G-G- F1-A2-P3-E4-K5-E6-E7-X8-X9- R-NH2
V G-G- F1-A2-P3-E4-K5-X6-X7-P8-X9 R-NH2
VI G-G- X1-A2-P3-X4-K5-X6-X7-P8-X9 R-NH2
VII Ac- A1-A2-A3-A4-K5-X6-X7-X8-X9 R-NH2
VIII Ac- X1-A2-A3-X4-K5-X6-X7-X8-X9 R-NH2
Ac: acetylated N-terminus; -NH2: amidated C-terminus. 
Amino acid composition in the X positions of dedicated libraries V-VIII: 
X1: P, V, E, W, F 
X4: P, V, T, G, W, L, Y, N, E 
X6: Q, T, N, Y, F, V, G, L, A, P, E 
X7: G, L, F, A, E 
X8: P, E 
X9: G, Q, A, S, V, P, L, E, Y, D, M, F, W 
 
The positively charged lysine at position P5 and proline in position P3 or P8 are 
defined amino acids. The side chains of amino acids in these three positions point 
away from the binding groove (Fig. 3) and there are no main chain hydrogen bonds in 
position P3 and P8 (Fig. 1). We used these amino acids in non-anchor positions to 
ensure that all library peptides bind in a uniform register. If the binding frame is 
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shifted by one position, the positively charged side chain of lysine would point into 
the positively charged pocket of the binding groove. In addition, essential main chain 
amide nitrogen hydrogen bonds would be abolished by proline in any of the positions 
P2, P4, P6, P7 and P9.  
 
Alanine is another defined amino acid we used in our libraries. The side chain of 
alanine is too short to be expected to act as a prominent anchor residue, at least in 
pockets which are deep. Library VII in table 2 for example is completely anchorless at 
the N-terminal part of the sequence; this will in theory focus the selection pressure on 
the four C-terminal X positions.  
 
Libraries I-VI are extended by glycine residues in order to allow formation of 
hydrogen bonds in positions P-1 and P-2 (Fig. 1). It has been shown that additional 
hydrogen bonds N-terminally of the peptide binding frame increase the binding 
affinity to HLA-DQ2.5 (Bartnes et al. 1999;McFarland et al. 1999;Nelson and 
Fremont 1999). Libraries VII and VIII are acetylated in position P1. N-terminal 
acetylation instead of extension is minimizing the risk for register shifting, but retains 
the possibility to generate one of the hydrogen bonds N-terminally of the binding 
frame.  
 
The C-terminal arginine (R) in position P10 of all of our peptide libraries is included 
to prevent shifting and to enhance signal intensities of peptides and their y-fragments 
in mass spectrometry.  
 
In libraries I-IV, X is denoting an equimolar distribution of 19 natural L-amino acids 
(excluding cysteine). Peptide libraries with many fully randomized X positions are too 
complex and difficult to analyze, therefore we used dedicated X positions in the 
libraries V-VIII. 
 
4.2. Synthesis of peptides and peptide libraries 
For this work, peptide libraries as well as single peptides were synthesized. Peptide 
libraries were used to identify peptides with highest affinity from a mixture of 
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sequences. Individual peptides were used in peptide binding experiments to determine 
relative binding affinities of the identified ligands. 
 
All single peptides and peptide libraries I-IV were synthesized on a pipetting robot 
(Syro I) using a standard Fmoc (Fluorenylmethoxycarbonyl)/HBTU (2-(1H-
Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) strategy on 
solid supports (mainly Rink amide MBHA-resin). Randomized library positions (X) 
were introduced by two coupling steps using amino acid mixtures in an equimolar 
ratio with respect to the coupling sites of the resin. The identity of the single peptides 
was confirmed by MALDI-TOF MS, and the purity was determined by RP-HPLC. 
Some single peptides were acetylated at their N-terminus, others were labeled with a 
fluorophore or a radio label (125I). Such labeled peptides were used as reporters in 
peptide binding assays, such as the HLA-DQ2.5 high affinity ligand P198 
(KPLLIIAEDVEGEY, Mycobacterium bovis 65kDa Hsp 243-255Y). The radio-
labeling with 125I was done with the chloramine T method (Greenwood et al. 1963).  
 
4.3. HLA-DQ2.5 as full length molecule or soluble construct 
Different HLA-DQ2.5 reagents were used for various experiments. Besides detergent-
solubilized full length molecules, we used recombinant water soluble HLA-DQ2.5 
constructs.  
 
For peptide binding assays with the radioactively labeled reporter peptide, we used 
detergent-solubilized HLA-DQ2.5 (DQA1*0501, DQB1*0201). These full length 
molecules were derived from Epstein-Barr virus-transformed B lymphoblastoid cell 
lines (Johansen et al. 1994). 
 
For identification of optimal binders from the peptide libraries and for measuring 
HLA-DQ2.5 binding affinities of high affinity binders, we chose a water soluble 
recombinant construct carrying an -I-gliadin peptide covalently attached to the -
chain by a thrombin cleavable linker (sDQ2-I). These molecules were produced in 
high purity by baculovirus transfected Sf9 insect cells, which can be grown in spinner 
cell cultures (Quarsten et al. 2001).  
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Water soluble HLA-DQ2.5 without a tethered peptide (sDQ2) was expressed in a 
stably transfected Drosophila melanogaster S2 cell line. In these constructs the 
extracellular parts of the DQ- and DQ-chain are fused with a Fos- and a Jun zipper, 
respectively (Paulsen et al. unpublished). The S2 cells were also grown in cell spin 
flasks at 22ºC in serum free media. The secretion of sDQ2 into the medium was 
induced by CuSO4. As described in paper I, these molecules co-purified with the 
insect cell derived protein DCB-45.   
 
All of our HLA-DQ2.5 molecules were affinity purified from the culture media or cell 
lysate using the specific, monoclonal antibody 2.12.E11 bound and cross-linked to 
protein A-sepharose (Johansen et al. 1994;Viken et al. 1995). Protein concentrations 
were measured using a BCA kit and purity was checked by SDS-PAGE. 
 
4.4. Isolation and identification of high affinity HLA ligands from peptide 
libraries
For this approach we used water soluble HLA class II molecules and soluble 
dedicated peptide libraries. A limited amount of thrombin treated sDQ2-I was 
incubated with a complex peptide library composed of a large number of different 
sequences in a defined format, together with soluble HLA-DM. After two days of 
incubation at 37°C and pH 5.3, the library peptides bound to sDQ2 were isolated from 
the excess of free peptides by preparative size exclusion chromatography. Then, the 
protein fraction was concentrated and the pH was adjusted to 1 in order to release 
bound peptides. The eluted peptide fraction was purified and desalted using a reverse 
phase material. Samples were analyzed by MALDI-TOF MS using an Ultraflex II 
instrument or by nLC-MS/MS using an LTQ-Orbitrap XL mass spectrometer. Peptide 
libraries with one fully randomized X position (libraries I and II in table 2) were 
analyzed by MALDI-TOF MS and the peptide sequences were identified manually 
from the acquired mass spectra. More complex libraries (libraries III-VIII) were 
analyzed with nLC-MS/MS and data were searched against a library defined database 
by using the Proteome Discoverer software and the Mascot search engine.  
 
The format of the more complex peptide libraries allows for peptides with isobaric 
amino acid combinations. Such isobaric peptides share most of their fragment ion 
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masses. Therefore a manual inspection of all MS/MS events for which Mascot 
assigned several isobaric peptides as significant was necessary. The manual 
inspection included a comparison of the observed fragmentation pattern with the 
theoretical fragmentation of all assigned hits. Further, since isobaric peptides often 
elute at slightly different time points, we could compare the elution profiles and 
retention times for most of the isobaric peptides in the sample selected by HLA-
DQ2.5 with the corresponding elution profile and retention times of peptides in the 
original library sample.  
 
4.5. Peptide binding assays 
To assess the relative binding affinity of single peptides, we used two different 
peptide binding assays. In both assays we measured the ability of the test peptide to 
compete with a high affinity indicator peptide for HLA-DQ2.5 binding. The binding 
affinity of a peptide is usually defined by its IC50 value, which is the concentration of 
this peptide needed to inhibit 50% of the binding of the indicator peptide.  
 
In the binding assay with the radioactively labeled P198 indicator peptide, we used 
detergent solubilized full length HLA-DQ2.5, a simple spin column separation 
method and a gamma-counter (Buus et al. 1995;Johansen et al. 1994). IC50 values 
were calculated from the radioactivity bound to HLA-DQ2.5 (in the void volume) and 
the unbound radioactivity (radioactive indicator peptide on the column). 
 
For measuring IC50 values of peptides with high affinity, sDQ2-I was used together 
with a carboxyflourescein labeled P198 indicator peptide. After incubation, the 
protein fraction was separated from the unbound peptides by size exclusion 
chromatography. The UV (214nm) and the fluorescence signal (Ex. 490nm, Em. 
520nm) were monitored. IC50 values were calculated on the basis of the heights of 
the fluorescence signal to the corresponding UV signal. 
 
Notably, IC50 values derived from these two assays can not be directly compared to 
each other. One reason is the difference in detection sensitivity. Detection of a 
fluorescent indicator is less sensitive compared to the detection of radioactivity. 
Therefore, the fluorescent indicator peptide is used in a higher concentration, which in 
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turn requires more competitor peptide to achieve a 50% inhibition. Another reason 
might be the slower peptide exchange for sDQ2-I which is probably caused by the 
slower off-rate of the DQ2--I-gliadin epitope compared to the diverse repertoire of 
ligands bound to detergent solubilized HLA-DQ2.5. We tried to adjust for this by 
allowing peptide exchange over 48 hours instead of 12 hours. 
 
To be able to compare results from two different experiments, we used several 
reference peptides in each assay. We then calculated relative binding capacities 
(RBC) for each test peptide by dividing the IC50 values of the test peptide by the 
IC50 value of the reference peptide P198.  
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5. Discussion
5.1. Interfering with the presentation of immunogenic epitopes by HLA 
Most autoimmune diseases are associated with HLA molecules. HLA-DQ2.5 
(DQA1*0501, DQB1*0201) is part of the B8-DR3-DQ2 haplotype and strikingly, this 
haplotype is associated with particularly many diseases, including CD, type 1 
diabetes, systemic lupus erythematosus and Addison’s disease (Sollid et al. 
1989;Thorsby 1997;Thorsby and Lie 2005;Todd et al. 1987). In CD, HLA-DQ2.5 on 
the surface of APCs plays a key role in the pathogenesis by presenting gluten peptides 
to specific CD4+ T cells in the intestinal mucosa (Lundin et al. 1993). More then 90% 
of the CD patients express HLA-DQ2.5 (Sollid 2002;Sollid and Thorsby 1993). If an 
agent could specifically and effectively interfere with antigen presentation by this key 
molecule, it would allow for a novel treatment strategy for CD and other HLA-DQ2.5 
associated diseases.  
 
Blocking the presentation and/or recognition of immunogenic gluten derived epitopes 
can be done in two different ways. So far, the most promising approach is the use of 
cyclic and dimeric gluten peptides which sterically hinder the interaction of the TCR 
with the HLA-DQ2.5:peptide complex. Thereby the activation of the specific CD4+ T 
cell is blocked (Xia et al. 2007). Another possible approach is the blocking of the 
HLA-DQ2.5 binding groove by using high affinity binders to this molecule, which 
can effectively out-compete gluten derived epitopes. Such a HLA blocker should 
however not be immunogenic by itself. Therefore, it would make sense to combine 
both approaches by designing bulky or cyclic peptides with high affinity to HLA-
DQ2.5. 
 
Although antagonising T-cell receptors is about 100 fold more efficient than blocking 
antigen presentation by MHC molecules (De Magistris et al. 1992), in CD this 
principle is unsuitable due to the TCR heterogeneity (i.e. different TCR recognizing 
the same peptide-MHC complex) as well as the fairly large number of different gluten 
T cell epitopes. Blocking HLA-DQ2.5 might be the only way to specifically interfere 
with antigen presentation. For this purpose, specific high affinity binding molecules 
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have to be created, feasible to block the HLA-DQ2.5 binding groove for gluten 
derived antigens.  
 
Since professional APCs express up to several hundred thousand MHC molecules on 
their surface (Stevanovic and Schild 1999;Sykulev et al. 1996) and because as little as 
0.01%-0.1% of MHC:peptide complexes are needed to elicit a T-cell response, 
virtually a blockage of 100% has to be reached with MHC blockers to prevent T-cell 
activation (Christinck et al. 1991;Demotz et al. 1990;Harding and Unanue 1990). 
Therefore, the binding affinity of a peptide blocker for HLA-DQ2.5 should be several 
magnitudes higher than the binding affinities of gluten derived antigens. 
 
Presumably, no combination of natural amino acids will fulfil such requirements for 
blockers. Therefore, the next essential step in blocker development will be to explore 
if non-natural amino acids can increase the peptide binding affinity to HLA-DQ2.5. 
Such modified amino acids have to be used at certain positions to optimize fitting and 
subsequently increase binding affinity.  
 
5.2. Methods for identification of HLA binding motifs and optimal binders 
Methods to identify peptide binding motifs and optimal ligands to HLA molecules are 
important in basic and applied research. Identification of a binding motif helps to 
understand underlying mechanisms of HLA associated diseases and to identify 
potential T-cell epitopes in protein sequences. The identification of optimal ligands is 
fundamental for the design of new drugs and vaccines as treatment for HLA 
associated diseases.  
 
A variety of different techniques and methods have been used to elucidate peptide 
binding. In the traditional approaches, membrane bound HLA molecules are isolated 
from EBV-transformed B lymphoblastiod cells and the natural ligands of these 
molecules are eluted and sequenced. Further, these peptides are synthesized and their 
binding affinity is measured. By systematic truncation and single amino acid 
substitution experiments, the binding frames are identified and rules governing 
binding are established. In other approaches for HLA epitope identification, 
overlapping peptides covering the total sequence of a candidate protein are 
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synthesized, followed by direct or indirect binding assays. A different approach is the 
use of bacteriophages which can display various peptides (M13 phage display). These 
peptides can be overlapping sequences of a candidate protein or represent randomized 
peptide libraries (Hammer et al. 1992). Peptide displaying phages are incubated with 
the HLA molecule of interest. Those phages which bind to HLA are isolated and 
amplified, and subsequently the sequence of the peptide ligand is determined by 
sequencing the corresponding phage DNA. 
 
For the investigation of high affinity binding and the potential benefits of non-natural 
amino acids however, peptide library based approaches provide several obvious 
advantages compared to the approaches described above. The format of synthetic 
peptide libraries can be adapted to the aim of the study. This is done by customizing 
the sequence length of the library, the alignment of binding registers and the numbers 
and composition of randomized positions. In addition, libraries of chemically 
modified amino acids can be included in any position.  
 
In paper II and III we present two different library based approaches which we used to 
explore high affinity binding to HLA-DQ2.5. First, by a positional scanning peptide 
library approach the solely influence of each natural amino acid in each position of 
the peptide binding register was measured in an otherwise fully randomized 
backbone. All amino acids which were measured in each position of the peptide 
binding frame could be ranked by their relative contribution for binding and sorted 
into categories of favorable and unfavorable amino acids. In paper II we show that by 
simply combining the most favorable amino acids we were able to design high 
affinity binders. The 10mer composed of the best amino acids in each position was 
shown to be a 50-fold better binder to HLA-DQ2.5 than the immunodominant DQ2--
I-gliadin peptide. This peptide was the best binder to HLA-DQ2.5 that we ever tested. 
 
To further explore the rules for high affinity binding, we developed a novel peptide 
library based method (paper III), allowing us to search for optimal binders in complex 
peptide libraries with one or two fully randomized or several dedicated X positions. 
This new method also allows us to include non-natural amino acids in any position of 
the peptide binding frame. 
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5.3. Optimizing fitting to increase binding affinity to HLA-DQ2.5 
5.3.1. Optimizing anchors 
The crystal structure of HLA-DQ2.5 with the immunogenic gluten derived DQ2--I-
gliadin epitope (QLQPFPQPELPY) was solved with a resolution of 2.2 Å (Kim et al. 
2004). Peptide binding is mediated by a strong hydrogen bonding network, composed 
of 13 hydrogen bonds from the peptide main chain to HLA-DQ2.5. Binding energy is 
also contributed by the fitting of amino acid side chains into the five pockets in the 
peptide binding groove (P1, P4, P6, P7 and P9) (Fig. 4A). Notably, the overall charge 
of the binding groove is positive, especially in the area of the pockets P4, P6 and P7, 
which explains the bias for negatively charged anchor residues found in these 
positions in gluten derived epitopes as well as in other ligands.  
 
Figure 4: HLA-DQ2.5 in complex with the immunogenic gluten derived DQ2--I-
gliadin epitope (QLQPFPQPELPY).  
(A) Looking from above into the peptide binding groove of the HLA-DQ2.5 
molecule. The surface of HLA-DQ2.5 is given in blue. The peptide is shown in 
yellow, with nitrogen marked blue and oxygen marked red. The pockets P1, 
P4, P6, P7 and P9 are labelled. 
(B) A side view of the peptide binding groove, focusing on peptide interaction with 
the pockets P1, P4 and P7. The HLA-DQ2.5 surface is shown as mesh, the 
peptide is yellow, with nitrogen marked blue and oxygen marked red. 
Figures were generated with PyMol (DeLano Scientific LLC) and by using the atomic 
coordinates of HLA-DQ2--I-gliadin (PDB ID code 1S9V). 
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Interestingly, the closer view into the HLA-DQ2.5 peptide binding groove occupied 
by the DQ2--I-gliadin reveals an imperfect fitting of the peptide side chains in some 
of the anchor positions. The anchoring residues in positions P1 and P7 interact only 
with the surface of the deep pockets (Fig. 4A and B) and the side chain in position P9 
is positioned outside, contacting the so called P10 shelf (Fig 4A). In a study by 
Kapoerchan et al., molecular modelling of the high affinity binder 
ADAYDYESEELFAA into the binding groove of HLA-DQ2.5 indicated that none of 
the natural amino acids are able to optimally occupy the large pocket P1 (Kapoerchan 
et al. 2010). Subsequently, the authors tested eight non-natural amino acids as anchor 
residues in position P1. Results from binding assays showed that binding affinities 
where increased of up to 2 fold.  
 
In experiments using a HLA class I molecule (HLA B*2705, linked to ankylosing 
spondylitis), the authors reported an improved stability of the HLA-ligand complex 
after filling a hydrophobic binding pocket with a large non-natural aromatic side chain 
(Krebs et al. 1998).  
 
These experiments were the first to successfully explore high affinity binding by 
using modified amino acids. However, the systematic substitution with modified 
amino acids is a time consuming approach since only a few residues can be tested at 
the same time. With a peptide library format such as the one presented in paper III, 
the identification of more optimal anchor residues could be done in a faster high-
throughput fashion.  
 
5.3.2. Influence of non-anchor residues 
Residues in non-anchoring positions can also contribute to the overall affinity of a 
peptide to HLA class II molecules. In our experiments with a positional scanning 
peptide library (paper II) several residues in each of the non-anchoring positions 
showed a positive or negative effect on peptide binding. Several previous reports 
discuss effects of those non-anchor residues. Position P3 is one of the four non-anchor 
positions, but it has been referred to as a shelf with peculiar selectivity in several class 
II molecules: HLA-DR1 and HLA-DR3 (Ghosh et al. 1995;Stern et al. 1994), HLA-
DQ6.4 and HLA-DQ6.2 (Ettinger et al. 2006) and HLA-DQ2.2 (van de Wal et al. 
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1997). In position P3, the side chain of the peptide has been shown not to point 
directly outward in the direction of the TCR like the side chains in the other non-
anchor positions P2, P5 and P8. For example, the methionine of the CLIP peptide in 
the binding groove of HLA-DR3 is only 30% solvent exposed (Ghosh et al. 1995). In 
some reports on the non-disease-associated HLA-DQ2.2 molecule, the peptide residue 
in the position P3 is even specifically involved in peptide binding and therefore 
referred to as an additional anchor (van de Wal et al. 1997). Binding experiments have 
shown that HLA-DQ2.2 does not accept proline, histidine, arginine and lysine in this 
position. The disease associated HLA-DQ2.5 surprisingly does not seem to use an 
auxiliary P3 pocket (Ghosh et al. 1995;van de Wal et al. 1997). Indeed, the results 
from the positional scanning peptide library study (paper II) illustrate that position P3 
in HLA-DQ2.5 is a typical non-anchor position. None of the amino acids measured in 
this position reached a high relC value. There is no particular positive effect of any 
amino acid in any of the four non-anchor positions, but nevertheless, some residues 
were found which slightly increased the overall binding affinity of the peptide sub-
library, whilst others decreased binding affinities. Interestingly, only in the non-
anchor positions relC values drop as far as -2.9. This might give some indication on 
the negative effect of non fitting amino acids in these positions. 
 
To conclude, high affinity HLA class II ligands should not only have five optimal 
anchor residues, but also optimized residues in non-anchoring positions in order to 
increase the overall binding affinity. In the approach presented in paper II, we 
describe high affinity binders which were designed from the most favorable amino 
acids in each of the nine positions of the peptide binding frame. 
 
5.4. Advantages of a water soluble approach 
Screening experiments with peptide libraries are often performed on solid phase 
supports with the peptide bound via a linker to a resin (Lam et al. 1991). The main 
advantage related to this method is the rather easy detection, isolation and 
identification of bead-bound peptides (Lam et al. 2003). However, with peptides and 
proteins in solution, binding kinetics is much faster and there is no need for linkers 
and detachment from resin. Furthermore, unspecific binding, e.g. due to hydrophobic 
interactions with the solid phase, is reduced. Soluble peptide libraries can be used in 
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higher concentrations and/or smaller volume compared to bead based library 
approaches of the one-bead one-peptide format. The numbers of unique sequences 
present in the incubation mixture can be increased tremendously, giving a stronger 
selective force in the binding to a limited amount of HLA molecules. In addition, we 
use water soluble HLA-DQ2.5 molecules which allow us to work without detergent.  
 
5.5. Limitations of the soluble peptide library approach applied 
5.5.1. Sliding of the binding frame 
The libraries I-VI in table 2 are N-terminally extended by two glycine residues in 
order to allow formation of hydrogen bonds in the positions P-1 and P-2 (Fig. 1). It 
has been shown that these additional hydrogen bonds increase the binding affinity of a 
peptide to HLA-DQ2.5 (McFarland et al. 1999). However, the most abundant amino 
acid we identified in the X positions of the samples eluted from HLA-DQ2.5 after 
incubation with libraries V and VI did not fit into the known peptide binding motif. 
The skewed distribution of the most abundant amino acids is probably caused by 
sliding of some of the sequences into an alternative frame, which is exemplified for 
library VI in table 3.  
 
frame Relative positions 
 -P2 -P1 P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12
1 G G X A P X K X X P X R   
2   G G X A P X K X X P X R 
 
Table 3: Peptides of library VI registering in two different binding frames. Residues 
within the 9mer core region of the peptide binding site are given in bold. Amino acids 
are given in the one letter code. X represents dedicated positions (composition of each 
X position is defined in table 2). 
 
Efforts to circumvent sliding included the placement of proline in position P3 and P8 
and lysine in position P5. We expected that these two amino acids would force all 
sequences in binding frame 1 (Table 3). Proline is a special amino acid, as it can not 
participate in the hydrogen bonding network of the peptide main chain and therefore it 
is not preferred in the positions P2, P4, P6, P7 and P9. Lysine, a positively charged 
amino acid, is not favored in any position of the binding groove, but it is accepted in 
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position P5 due to its orientation towards the solvent. After sliding into binding frame 
2, both proline residues have moved into positions where no hydrogen bonds to the 
main chain nitrogen are formed. Lysine, however, is moved into position P7. In this 
position, lysine is expected to introduce a penalty, but eventually it will be accepted if 
all other anchor residues in the bound peptide are optimal. Thus, introducing of 
selected amino acids into certain positions of the peptide binding frame does not 
guarantee that all peptides bind in the same register. N-terminal extension should be 
avoided and instead acetylated libraries should be used. 
 
5.5.2. Libraries with too high complexity 
A fully randomized nonapeptide library is composed of 199 (3.23*1011) unique 
sequences. In 1mg of such a peptide library, each sequence is theoretically present 
with about 0.003 fmol, which is not enough for sequence identification. In our peptide 
libraries we decreased complexity by using dedicated X positions mainly placed in 
anchor positions. Such dedicated positions carried a reduced number of selected 
amino acids. Library VIII with 6 X positions is the dedicated library with the highest 
complexity and it contains 64 350 unique peptide sequences. When we analyzed 0.4 
μg of the original library on an LTQ-Orbitrap XL mass spectrometer online coupled 
to a nano-LC system, a Mascot search of the obtained LC-MS/MS data using a 
peptide library-defined database identified only 3% of the theoretical peptides, even 
though each peptide was theoretically present in pico-mol amounts (paper III). The 
peptides in our libraries have very similar sequences and therefore similar 
physicochemical properties. One dimensional LC separation might therefore be 
insufficient as many peptides show overlapping elution profiles. Thus, the Orbitrap 
will primarily select parent ions with high intensities for fragmentation, limiting the 
total number of identified peptides. In addition, our peptide libraries contain many 
isobaric peptides. These are peptides with identical molecular weight but different 
sequences. As co-eluting isobaric peptides will be fragmented together, they produce 
overlaying fragmentation patterns and therefore complicate sequence identification by 
Mascot and manual data inspection. 
 
After incubation with HLA-DQ2.5 and elution of bound library peptides, the 
complexity of the samples is dramatically reduced and little co-elution is thus 
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expected. However, the Mascot search engine which we used to analyze our data 
showed limitations when analyzing complex synthetic peptide mixtures composed of 
very similar sequences. This program is designed and optimized for protein 
identification (Perkins et al. 1999). In our dataset, Mascot is assigning all isobaric 
peptide variants of an identified parent mass as significant, because they share most of 
their y- and b-fragments. Such events have to be inspected manually, in order to 
exclude potential false positive hits. In experiments with highly complex libraries, this 
step of manual inspection can be very time consuming.  
 
5.6. Further optimization of the soluble peptide library approach 
Our soluble peptide library approach can easily be adapted to study high affinity 
binders containing non-natural amino acids. I would suggest the following workflow: 
In a first step, nine 1X sub-libraries should be synthesized using a complex mixture of 
non-natural amino acids in each X position. The amino acid composition of each X 
position could be adapted to the characteristic features of the corresponding anchor or 
non-anchor position. After selection by HLA-DQ2.5, the most optimal amino acids in 
each position will be identified. In a second step, these optimal residues could be 
combined to new libraries with up to nine dedicated X positions to identify the 
optimal combination of non-natural amino acids. Mascot can handle non-natural 
amino acids and manual inspection is not required provided that no isobaric peptides 
are created in the dedicated libraries. 
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6. Conclusion
 
MHC molecules have developed to present a large collection of intra- and 
extracellular protein fragments. The limited set of different MHC molecules that one 
individual expresses must be able to display an universe of different antigens for T-
cell recognition. Nevertheless, the peptides each molecule is presenting fit a more or 
less restricted peptide binding motif. MHC class I molecules are thought to be able to 
bind up to 10,000 different sequences (Stevanovic and Schild 1999). According to the 
peptide binding motif of HLA-DQ2.5 presented in table 1, it is theoretically possible 
to design 788,000,000 sequences with at least moderate affinity to this molecule, 
simply by combining the favorable residues in anchor positions with 19 natural amino 
acids in each of the non-anchor positions.   
 
Since many HLA molecules are associated with autoimmunity, efforts are made to 
identify peptide binding motifs and epitopes. Further, peptide blockers and 
antagonists which can interfere specifically with the presentation of immunogenic 
peptides are interesting treatment options for diseases with strong HLA association. 
CD is a model disease in this research field. The HLA-DQ2.5 molecule is strongly 
associated with CD and presents various gluten fragments to a variety of gluten 
specific HLA-DQ2.5 restricted CD4+ T cells. One peptide blocker to this molecule 
would treat all CD patients (DQ2.5+; DQ8-), independently of their CD4+ T-cell 
specificity.  
 
But do we need new treatment options for CD? The currently available treatment for 
CD is a gluten free diet (GFD). The benefit:risk ratio of the GFD treatment is very 
good. Unfortunately, as gluten is a widely used additive in the food industry, it is 
potentially present in all industrial processed foodstuffs. Gluten free food usually is 
expensive, often it does not taste as good and it is not available everywhere. There are 
many reasons why patients find it challenging to stick to their diet and for those with 
little or no gastrointestinal symptoms it is even harder.  
 
A highly efficient HLA-DQ2.5 blocker is thought to allow a very specific treatment 
for CD. Optimally, such a blocker should be administered orally. For this application 
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route, it must be stable to digestion and must cross the intestinal epithelium for 
blocking all HLA-DQ2.5 molecules in the lamina propria. High affinity binding 
peptides with several proline residues or chemically modified amino acids are 
expected to be poor substrates for proteases. The transport route of gluten derived 
peptides is still unknown, but hopefully, small peptide-like blockers would use the 
same route. The biggest challenge however remains: the generation of a peptide with 
such a high affinity that it can block in physiological concentrations selectively all of 
the HLA-DQ2.5 molecules in the lamina propria. This peptide is not likely to be 
composed of natural amino acids, but it must contain optimized non-natural amino 
acids in some if not all positions of the binding frame.  
 
If we would succeed in designing an effective blocker for this very well described 
HLA molecule, it would not only be of benefit for CD patients, but it would also give 
us valuable information about a possible new treatment option for other HLA 
associated diseases.  
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Table 1: the correct sequence for peptide P198 is KPLLIIAEDVEGEY 
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Abstract We here describe that soluble HLA-DQ2 (sDQ2)
molecules, when expressed in Drosophila melanogaster S2
insect cells without a covalently tethered peptide, associate
tightly with the D. melanogaster calcium binding protein
DCB-45. The interaction between the proteins is stable in S2
cell culture and during affinity purification, which is done at
high salt concentrations and pH 11.5. After affinity purifica-
tion, the sDQ2/DCB-45 complex exists in substantial
quantities next to a small amount of free heterodimeric
sDQ2 and large amounts of aggregated sDQ2 free of DCB-
45. Motivated by the stable complex formation and our
interest in the development of reagents which inhibit HLA-
DQ2 peptide binding, we have further characterized the
sDQ2/DCB-45 interaction. Several lines of evidence indicate
that an N-terminal fragment of DCB-45 is involved in the
interaction with the peptide binding groove of sDQ2. Further
mapping of this fragment of 54 residues identified a
pentadecapeptide with high affinity for sDQ2 which may
serve as a lead compound for the design of HLA-DQ2
blockers.
Keywords HLA . sDQ2 . DCB-45 . S2 .
Protein interactions . Peptide binding
Introduction
HLA-DQ2 (DQA1*0501/DQB1*0201) is associated with
several immune-mediated disorders including celiac disease
(Sollid et al. 1989; Thorsby and Ronningen 1993; Todd et
al. 1987). In order to develop specific blockers as a
potential future treatment for celiac disease and other
HLA-DQ2 associated diseases, there is a need to define
high affinity ligands for HLA-DQ2. The development of
such blockers will be facilitated by the production of
recombinant HLA-DQ2 that can be made in high quantities
and utilized for binding studies. On this background, we
have produced recombinant, soluble HLA-DQ2 (sDQ2)
molecules in either stably transfected S2 cells or in
baculovirus infected Sf9 cells. Interestingly, when express-
ing sDQ2 in S2 cells without a covalently bound peptide
that occupies the binding groove, we obtained remarkably
high amounts of stable molecules. Further analysis of these
sDQ2 molecules revealed that a major proportion of the
molecules copurifies with the Drosophila melanogaster
calcium binding protein DCB-45, a homolog to the D.
melanogaster supercoiling factor (SCF; Kobayashi et al.
1998). Given the apparent ability of the protein to stabilize
sDQ2, we hypothesized that it could contain a peptide
which binds efficiently to the binding groove of sDQ2 and
which could function as a lead peptide for the development
of HLA-DQ2 blockers. Here, we report on the identifica-
tion and characterization of the DCB-45 sequence which
mediates binding to sDQ2. Next to characterizing the
interaction between sDQ2 and DCB-45, our observations
are of general relevance for expression of recombinant
major histocompatibility complex (MHC) class II mole-
cules in S2 cells.
Immunogenetics (2009) 61:81–89
DOI 10.1007/s00251-008-0338-7
U. Jüse (*) :B. Fleckenstein : E. Bergseng : L. M. Sollid
Centre for Immune Regulation, Institute of Immunology,
University of Oslo,
Oslo, Norway
e-mail: ulrike.juse@medisin.uio.no
U. Jüse : L. M. Sollid
Institute of Immunology, Rikshospitalet University Hospital,
0027 Oslo, Norway
Materials and methods
HLA expression and purification
Water soluble HLA-DQ2 (DQA1*0501/DQB1*0201) was
expressed in a D. melanogaster S2 cell line by cotransfec-
tion of three vectors: a pMtal vector with the sequence
encoding for the extracellular part of the DQα-chain fused
to the Fos zipper, a pMtal vector with the sequence
encoding the extracellular part of the DQβ-chain fused to
the Jun zipper, and a pCoHYGRO resistance vector
(Paulsen et al., unpublished). The construct did not include
a sequence for a high affinity peptide ligand tethered to the
β-chain. The stably transfected S2 cells were grown in 1L
cell spin flasks at 22°C in serum-free media (Insect-
XPRESS™, BioWhittaker, Walkersville, MD, USA), con-
taining 300 μg/ml hygromycin B (Invitrogen, Carlsbad,
CA, USA) and 25 μg/ml garamycin (Schering-Plough,
Kenilworth, NJ, USA). The pMtal vectors contain a metal-
lothionein promoter and the production of sDQ2 was
induced by 100 mM CuSO4 over 3 days. From cell culture
supernatants, the sDQ2 molecules were affinity-purified like
previously described (Quarsten et al. 2001). HLA-DM
molecules were produced as soluble molecules in transfected
S2 cells (kind gift of Elizabeth Mellins) and purified by
FLAG-tag immunoaffinity chromatography and size exclu-
sion chromatography as described (Sloan et al. 1995).
Detergent-solubilized HLA-DQ2 (DQA1*0501/DQB1*0201;
EBV-DQ2) molecules were purified from Epstein–Barr virus-
transformed B lymphoblastoid cell lines as previously
described (Johansen et al. 1994). The protein concentration
of the various HLA molecules was determined by a BCA
protein assay kit (Pierce, Rockford, IL, USA).
Size exclusion chromatography and gel electrophoresis
Preparative size exclusion chromatography was performed
on an Äkta purifier system (Amersham Biosciences Corp.,
Piscataway, NJ, USA) using a Superdex 200 10/300 GL
column (Amersham Bioscience). Proteins were separated by
isocratic elution (flow rate 0.75 ml/min) using phosphate
buffered saline (PBS; pH 7.3) and monitored at 280 nm.
One-dimensional sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) was performed using 6–12%
polyacrylamide gels. Samples were reduced by heating in
Laemmli buffer containing 1% β-mercaptoethanol (95°C,
5 min). Proteins were stained by Coomassie Blue.
Trypsin treatment
For protein identification by peptide mass fingerprinting,
protein bands were excised from the Coomassie Blue
stained gel and in-gel digested as previously described
(Fleckenstein et al. 2004). For the acetylation of primary
amino groups, the gel pieces were incubated in 3%
acetanhydride/0.1 M NaHCO3 pH 8.4 for 2 h at room
temperature, followed by several washing steps and tryptic
digestion. Partial digestion of the sDQ2/DCB-45 complex
in solution was performed with N-tosyl L-phenylalanyl
chloromethyl ketone (TPCK) trypsin agarose beads
(Pierce). For 24 μg protein, 4.8 μl bead suspension in
0.1 M NH4HCO3 buffer in a total volume of 22.8 μl was
used. The samples were incubated for 17 min at 37°C under
rotation. For size exclusion chromatography, the beads were
removed by filtration.
Mass spectrometry
Matrix-assisted laser desorption–ionization time-of-flight
mass spectra (MALDI-TOF MS) were acquired on a
MALDI-TOF/TOF instrument (Ultraflex II, Bruker Daltonics,
Bremen, Germany). Tryptic peptide mixtures and peptides
eluted from sDQ2were desalted and concentrated on Poros 20
R2 reverse-phase packing sorbent (Applied Biosystems,
Foster City, CA, USA) packed in 20-μl GELoader tips
(Eppendorf, Hamburg, Germany). Peptides were eluted onto
a stainless steel target plate using 70% acetonitrile, containing
0.1% trifluoroacetic acid (TFA) and 10 g/l α-cyano-4-
hydroxycinnamic acid. Synthetic peptides were also analyzed
using α-cyano-4-hydroxycinnamic acid, but then samples
were applied as a dried droplet.
Peptide synthesis
Peptides with a length of 11–20 amino acid residues were
synthesized on Rink amid methylbenzhydrylamine-resin
using Fmoc/2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyl-
uronium hexafluorophosphate (HBTU) chemistry and a
pipetting robot (Syro I, MultiSynTech, Bochum, Germany).
Coupling was performed with a tenfold molar excess of
each Fmoc-L-amino acid and HBTU and a 15-fold excess
of N,N-diisopropylethylamine. Piperidine (20% in dime-
thylformamide) was used for Fmoc deprotection and 96%
TFA containing 2% triisopropylsilane and 2% water were
used for side chain deprotection and cleavage from the
resin. The identity was confirmed by MALDI-TOF MS,
and the purity was determined by analytical reversed-phase
high performance liquid chromatography (HPLC; Agilent
1100 system, Agilent Technologies, Santa Clara, CA, USA)
using a Zorbax C18 column (Agilent Technologies). The 54
residue long peptide was synthesized on 10 mg NovaPEG
Rink Amide resin LL (Novabiochem®, Merck KGaA,
Darmstadt, Germany) with a low loading capacity of
0.16 mmol/g. The pseudoproline dipeptides Fmoc-Gly-
(Hmb)Gly-OH (Novabiochem) in position 24 and Fmoc-
Glu(OtBu)-Ser(ψMe,Mepro)-OH (Novabiochem) in position
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41 and 52 were used to substitute for Gly-Gly and Glu-Ser,
respectively. The secondary amide bond of these amino
acid surrogates is reversibly protected and cleaved during
deprotection with 96% TFA. The first 30 cycles were run
under standard conditions as described above. From
cycle 30 on, all coupling steps were repeated and 30%
piperidine in dimethylformamide for Fmoc deprotection
was used. Side chain deprotection and cleavage from the
resin was performed as described above. From the crude
peptide, the observed TFA ester on the N-terminal Ser side
chain was removed by treatment with 1 M NaOH for
30 min, followed by neutralization with equimolar amounts
of HCl. The identity and purity were determined like
described above.
Labeling of synthetic peptides
The HLA-DQ2 high affinity ligand P198 (KPLLIIAEDVE-
GEY, Mycobacterium bovis 65 kDa Hsp 243–255Y) was
either fluorescently labeled or radiolabeled. The radio-
labeling with 125I was done with the chloramine T method
(Greenwood et al. 1963). Fluorescence labeling was done
by N-terminally coupling of 5(6)-carboxyfluorescein (CF)
using 5 equivalents CF and 6 equivalents N,N-diisopropyl-
carbodiimide. The coupling step was repeated several times
until a negative Kaisertest was obtained (Kaiser et al.
1970). The fluorescently labeled peptide was cleaved from
the resin and analyzed as described above.
Peptide binding assays
Detergent-solubilized HLA-DQ2 (DQA1*0501/DQB1*0201;
EBV-DQ2) at concentrations of 0.1–0.2 μM was incubated
with the radioactively labeled P198 indicator peptide and
synthetic peptides at various concentrations as described earlier
(Johansen et al. 1994). The EBV-DQ2-peptide complexes
were subsequently separated from unbound peptides by size
exclusion chromatography in a spin column system as
described (Buus et al. 1995). The radioactivity in the void
volume and in the column material was counted by a γ-
counter (Wallac, Turku, Finland) and IC50 values were
calculated. sDQ2 (6.25 μM) or trypsin digested sDQ2
(6.25 μM) was incubated with CF-labeled P198 indicator
peptide (10 μM). In some instances, soluble HLA-DM
(sDM) was added in a concentration of 0.38 μM. The
incubation was performed in a total volume of 13 μl of a
citrate phosphate buffer (pH 5.3) at 37°C over 48 h. Next,
5 μl of each sample were transferred on a Zorbax GF 450
4.9×250-mm column and eluted with 150 mM PBS at a flow
rate of 1 ml/min using an Agilent 1100 HPLC system. The
UV signal (214 nm) and the fluorescence signal (Ex. 490 nm,
Em. 520 nm) were monitored. Peptide binding to sDQ2 was
quantified by measuring the area under the curve (AUC) of
the fluorescence signal for peaks with a maximum between
9.5 and 9.7 min (corresponding to sDQ2 with bound indicator
peptide). The mean values from at least two independent
experiments were plotted.
Results
Characterization of the sDQ2 preparation by SDS-PAGE
and size exclusion chromatography
The affinity purified sDQ2 was analyzed by SDS-PAGE
under reducing conditions. In addition to the bands of 35 and
25 kDa corresponding to the sDQ2 α- and β-chains,
respectively, a protein with an approximate molecular weight
of 50 kDa was observed (Fig. 1A). In size exclusion
chromatography under nonreducing conditions, the same
sample eluted in three peaks, which were fractionated for
further analysis by SDS-PAGE (Fig. 1B,C). As the first peak
eluted with the void volume, we consider it to represent
aggregates of sDQ2 with a size larger than 600 kDa. SDS-
PAGE analysis of this fraction (Fig. 1C, lanes a and e)
showed the presence of sDQ2 α- and β-chains, but no band
at 50 kDa. In the second fraction (Fig. 1C, lanes b and f), the
50-kDa protein was detected with similar intensity as the
sDQ2 α- and β-chains. Peak 3 mainly contains sDQ2 α- and
β-chain (Fig. 1C, lane c). The small amount of the 50-kDa
protein can be explained by the overlap of peak 2 and 3 and
the small amounts of peak 2 present in fraction 3. The
amount of protein applied to each lane of the SDS-PAGE
was calculated by combining the known amount of total
protein subjected to size exclusion chromatography and by
determination of the peak areas for each of the fractions 1–3.
This was 2.2 μg for each of the lanes a–c. For the lanes e
and f, 29 μg of protein of the fractions 1 and 2, respectively,
was loaded in each lane. The protein bands in the lanes a and
e (corresponding to fraction 1) appeared weaker compared to
the protein bands detected in the lanes b and f
(corresponding to fraction 2), although identical amount of
protein should have been loaded. This might be due to
aggregation of sDQ2 in fraction 1, leading to an incomplete
transfer into the gel.
Identification of the 50-kDa protein by peptide mass
fingerprinting
In order to identify the nature of the 50-kDa contamination,
the protein was subjected to tryptic in-gel digestion. The
digest was analyzed on a MALDI-TOF/TOF mass spec-
trometer and a MASCOT search reported the identification
of a D. melanogaster-derived SCF (accession number
Q9W0H8_DROME). Acetylation prior to digestion and
analysis by MALDI-TOF/TOF MS identified the tryptic
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peptide SSIPEELPHNPLEHDPLHPR as the N terminus of
the protein. The observed 50-kDa protein therefore repre-
sents a N-terminally truncated derivate of the D. mela-
nogaster calcium binding protein (DCB-45), which is
described as an elongated homolog of SCF (Kobayashi et
al. 1998). The identified protein is highly acidic with a pI of
4.27.
Limited digestion of sDQ2/DCB-45 complexes
To investigate the interaction between DCB-45 and sDQ2,
we subjected the obtained sDQ2 preparation to limited
tryptic digestion with immobilized TPCK trypsin. As
evaluated by SDS-PAGE, a digestion time of 17 min at
37°C was found to be optimal to fully degrade DCB-45
Fig. 2 Limited tryptic digestion
of the purified sDQ2 preparation
analyzed by SDS-PAGE (A) and
size exclusion chromatography
(B). B Overlay of the size
exclusion chromatograms of the
nondigested (broken line) and
trypsin treated sDQ2 preparation
(full line)
Fig. 1 Analysis of sDQ2 produced in S2 insect cells by reducing
SDS-PAGE (A, C) and size exclusion chromatography (B). A SDS-
PAGE of the purified sDQ2 preparation. B Analysis and fractionation
of the produced sDQ2 by size exclusion chromatography. C The three
fractions obtained in B were reanalyzed by SDS-PAGE. Lanes a–c,
fractions 1, 2 and 3, respectively (2.2-μg protein loaded); lane d,
molecular weight standard (BIO-RAD, precision plus protein™
standard); lane e and f, fraction 1 and 2, respectively (29 μg protein
loaded). Amounts of protein loaded onto the gel were calculated from
the known amount of total protein subjected to size exclusion
chromatography and determination of the peak area
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(Fig. 2A). Under these conditions, the sDQ2 α-chain
remains intact whereas most of the β-chain undergoes a
small truncation which does not interfere with formation of
a stable and functional heterodimer (see below). Size
exclusion chromatography of the same digested sample
demonstrated a complete disappearance of the sDQ2/DCB-
45 complex which eluted in peak 2 of the untreated sample
(Fig. 2B). Notably, the limited proteolysis resulted in a
significant increase of the signal intensity observed for peak
3. Following purification of peak 3, the sDQ2 in this
preparation was found to be stable for at least 2 days when
coincubated at 37°C not only with the high affinity HLA-
DQ2 binding peptide P198 but also without adding peptide
for at least 24 h at 4°C (data not shown). This suggests that
sDQ2 in the partly digested sample remains as a stable
heterodimer with an occupied and thereby stabilized
peptide binding groove. Peak 3 of the trypsin-treated
sDQ2 preparation (Fig. 2B) was concentrated over a
10-kDa spin filter (Vivaspin), washed with PBS, and
treated with 0.1% TFA to elute ligands occupying the
peptide binding groove. Analysis of the eluted peptides by
MALDI-TOF/TOF MS identified four tryptic peptides
which were all derived from the 54 N-terminal amino acid
sequence of DCB-45 (Fig. 3). These peptides share a 23
amino acid long core sequence (HFDGGEHNAQFD
HEAFLGPDESK), suggesting the interaction site is within
this region. Besides the DCB-45-derived peptides, we
found low signal intensities for several other peptides in
the MALDI-TOF spectrum. One of these peptides could be
identified as STEFSEDLLDEDLDLSDIDENEEEFLR, and
this fragment is derived from the D. melanogaster protein
RH45818p (Fig. 3).
Peptide binding ability of sDQ2/DCB-45 before
and after limited tryptic digestion
The sDQ2/DCB-45 complex (i.e., peak 2 in Fig. 2B, broken
line) was purified, and its peptide binding ability was
analyzed using the fluorescence-labeled HLA-DQ2 high
affinity ligand P198. Peptide binding to sDQ2/DCB-45 was
found to be poor, and also limited tryptic digestion of the
complex could only slightly increase binding of P198
(Fig. 4). In the presence of HLA-DM, however, binding of
P198 was remarkably increased, both for the trypsin treated
and untreated sDQ2/DCB-45.
Identification of the HLA-DQ2 peptide binding frame
and binding affinity of DCB-45-derived peptides
To further investigate whether the interaction between
DCB-45 and sDQ2 is involving the peptide binding groove,
we synthesized five 20-mer peptides with overlapping
sequences which covered the 54 amino acid long N-
terminal DCB-45 sequence (Table 1). The peptide binding
affinity was tested in the competition assay using the 125I-
labeled indicator peptide P198 and EBV-DQ2. In this assay,
the highest affinity was found for the 20-mer
PRHFDGGEHNAQFDHEAFLG. To identify the exact
binding frame, three 15-mer peptides covering this 20-mer
region were synthesized and tested. The best binding
sequence was found to be HNAQFDHEAFLGPDE with
an IC50 of 0.13 μM. The truncated peptide HNAQFD-
HEAFL also bound with a good affinity (0.77 μM),
suggesting AQFDHEAFL as the 9-mer core region medi-
ating HLA-DQ2 binding (Table 1). The IC50 value of the
Fig. 3 MALDI-TOF mass spectrum of acid-eluted peptides after
trypsin treatment and fractionation of the heterodimeric sDQ2 fraction
(peak 3; Fig. 2B). The sequences of the five peptides assigned by their
m/z values were determined by MALDI-TOF/TOF MS and are given
in the insert. Four of the identified peptides derive from DCB-45. The
9-mer, suggested as the core region interacting with the HLA-DQ2
peptide binding groove, is shown in bold face
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54-mer is higher than that of the best binding pentadeca-
peptide (Table 1), what can obviously not be explained by
the slightly lower purity of the 54-mer (72%). Likely, a
different secondary structure of the longer peptide hinders
the interaction with the peptide binding groove resulting in
the observed lower binding affinity.
Peptide binding specificity of sDQ2 compared to EBV-DQ2
The α-I-gliadin epitope and analogs were tested for binding
to sDQ2 and EBV-DQ2. For both DQ2 molecules, the
calculated relative binding capacity and the ranking of the
measured IC50 values for the set of peptides was found to
be nearly identical. This strongly indicates that the peptide
binding specificity of sDQ2 matches that of EBV-DQ2
(Fig. 5).
Discussion
In this study, we show that soluble HLA-DQ2 molecules
without a covalently tethered peptide ligand copurify with
the D. melanogaster-derived protein DCB-45, when
expressed in S2 insect cells. We identified the fragment of
DCB-45 which mediates the strong interaction with sDQ2
and obtained evidence indicating that a part of this fragment
is binding to the sDQ2 binding groove with high affinity.
The sDQ2 stabilizing effect of the DCB-45 protein
motivated us to unravel the basis for this interaction as
Fig. 4 Binding of the HLA-DQ2 high affinity ligand P198 to sDQ2/
DCB-45. Carboxyfluorescein-labeled P198 was incubated with the
purified sDQ2/DCB-45 complex with or without prior limited tryptic
digestion and in the presence or absence of soluble HLA-DM (sDM).
Binding was quantified in a gel-filtration assay and is given by the
fluorescence signal (AUC) measured for the sDQ2/DCB-45 complex
(undigested sample) or sDQ2 after limited digestion (digested
sample). The signals were observed at an elution time of 9.5–
9.7 min. Values were obtained from at least two independent
experiments; mean and standard errors are shown
Table 1 Binding of synthetic peptides to EBV-DQ2 given as IC50 values
Peptides IC50 [μM]
SSIPEELPHNPLEHDPLHPRHFDGGEHNAQFDHEAFLGPDESKKFDSLTPEESR 0.8a
SSIPEELPHNPLEHDPLHPR 51.1b
NPLEHDPLHPRHFDGGEHNA >167b
PRHFDGGEHNAQFDHEAFLG 0.56b
NAQFDHEAFLGPDESKKFDS 1.09b
LGPDESKKFDSLTPEESRRR 7.76b
LHPRHFDGGEHNAQF >167b
FDGGEHNAQFDHEAF 4.64b
HNAQFDHEAFLGPDE 0.13b
HNAQFDHEAFL 0.77b
KPLLIIAEDVGEY 0.09b
QLQPFPQPELPY 1.1a
PQPELPYPQPQLPY 7.4a
KPLLIIAEDVGEY 0.06a
IC50 is the peptide concentration required to give 50% inhibition of the binding of the indicator peptide (P198). The IC50 values for the peptides
presented in this table were analyzed in two separate sets of experiments. The results from one of three consistent titrations are given. As a
reference peptide, P198 (KPLLIIAEDVGEY) was included. The HLA-DQ2 binding frames are indicated in bold face
a In the first set of experiments, the binding affinity of the 54-mer peptide (72% pure) compared to gliadin-derived peptides P1269 (HLA-DQ2-α-I
epitope; QLQPFPQPELPY), P1274 (HLA-DQ2-α-II epitope PQPELPYPQPQLPY) and indicator peptide P198 was analyzed
b In the second set of experiments, the binding of overlapping synthetic peptides spanning the 54 amino acid long N-terminal region of DCB-45
was analyzed
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part of an effort to design compounds that can block HLA-
DQ2-mediated antigen presentation.
Expression of HLA class II molecules in insect cells is a
commonly used method for the production of recombinant
molecules (De Wall et al. 2006; Stern and Wiley 1992;
Wallny et al. 1995). Initially, DR1 and other MHC class II
molecules were expressed without a covalently tethered
peptide as so called “empty” class II molecules (Stern and
Wiley 1992). The expression of recombinant molecules
with a high affinity ligand covalently tethered to the N
terminus of the β-chain (Crawford et al. 1998), however,
gave improved expression and stable molecules and this
strategy thus developed as a preferred expression modality.
Our early work to express sDQ2 without a covalently
tethered peptide in the S2 cell system gave unusually high
protein yields and stable molecules what is in contrast to a
poor expression yield and unstable molecules obtained with
similar baculoviral constructs in Sf9 cells (Quarsten et al.,
unpublished). When analyzing and comparing peptide
binding specificity of these sDQ2 molecules with deter-
gent-solubilized HLA-DQ2 purified from EBV-transformed
B cells (EBV-DQ2), we found the same peptide binding
preferences but approximately a tenfold increase of the
IC50 values for each peptide when using the sDQ2
molecules (Fig. 5).
In mammalian antigen presenting cells the assembly of
HLA class II α- and β-chains is dependent on the invariant
chain (Ii) protein. In the ER, Ii is protecting and stabilizing
the class II binding groove with its class II-associated
invariant chain peptide (CLIP) sequence, and the Ii is
directing the class II molecules to the late endosomes where
HLA-DM catalyzes the exchange of CLIP for antigenic
peptides (Busch et al. 2005; Cresswell 1994). In S2 cells,
this mechanism for sDQ2 assembly and loading is missing.
One might thus expect that the unoccupied amphiphilic
peptide binding groove is rendering the class II molecules
unstable and prone to aggregation (Rabinowitz et al. 1998;
Vogt et al. 1997). For this reason, it has been argued that so-
called “empty” class II molecules are not truly empty but
filled with loosely bound peptides. We thus wanted to
characterize sDQ2 molecules produced in S2 cells in more
detail.
By SDS-PAGE analysis under reducing conditions, we
observed a strong band at 50 kDa in addition to the bands of
the sDQ2 α- and β-chains. A similar type of contamination
has not been observed with other soluble HLA molecules
produced in baculovirus infected Sf9 insect cells, nor in the
wild type EBV-DQ2 produced by EBV-transformed B cells.
This contaminating protein was identified as the D.
melanogaster-derived DCB-45 protein and our findings
suggest a tight interaction between sDQ2 and DCB-45. The
complex does not dissociate under the condition of high pH
and high salt concentrations used for elution from the
Fig. 5 Peptide binding specificity of sDQ2 compared to EBV-DQ2.
sDQ2 (1 μM) and EBV-DQ2 (0.3 μM) was incubated with the
radioactively labeled indicator peptide P198 (KPLLIIAEDVEGEY)
and titrations of competitor peptides. The HLA-DQ2-α-I gliadin
epitope (LQPFPQPELPY) and analogs were used. The bars show the
IC50 values (in μM). The relative binding capacity for each peptide is
given and was calculated as the ratio of the IC50 of the reference
peptide P198 to the IC50 of the test peptide. The Z in the amino acid
sequence denotes norvaline, X denotes 4-hydroxyproline. All peptides
marked with an asterisk (*) have an IC50 value higher than 167 μM
and the exact value could not be determined
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antibody affinity column (pH 11.5 and 2 M Tris), and
treatment at low pH resulted in precipitation rather in
dissociation of the two proteins. In contrast, the sDQ2
molecules found in the large aggregates (>600 kDa) appar-
ently are not associated with DCB-45, suggesting that sDQ2
is unstable in the absence of DCB-45. The sDQ2/DCB-45
interaction thus likely explains the observed high expression
yield of peptide-receptive sDQ2.
DCB-45 is a highly acidic protein (pI 4.27) and HLA-
DQ2 has a strong preference for binding negatively charged
residues in several of its anchor positions (Kim et al. 2004).
We therefore investigated whether the sDQ2/DCB-45 bind-
ing is also involving the peptide binding groove of sDQ2.
The characterization of such a strong interaction could be
helpful to design new lead structures for high affinity HLA-
DQ2 blockers. Such reagents have been discussed in the
treatment of celiac disease to inhibit HLA-DQ2-rectricted
presentation of gluten derived epitopes (Bergseng et al.
2005; Xia et al. 2006, 2007).
In the presence of HLA-DM, binding of the known
HLA-DQ2 ligand P198 to the isolated sDQ2/DCB-45
complex increased. The same effect of HLA-DM was
observed after limited proteolysis of this complex leading
to almost exclusive degradation of DCB-45 and a markedly
increase of heterodimeric sDQ2 (Fig. 2). Analysis by size
exclusion chromatography showed that this fraction was
stable. Interestingly, DCB-45-derived peptides could be
released at low pH and were found to originate from the N-
terminal 54-mer (Fig. 3). As these findings strongly
indicate a specific interaction of this region with the
sDQ2 peptide binding groove, a more detailed mapping
was performed. Using detergent-solubilized EBV-DQ2, the
pentadecapeptide HNAQFDHEAFLGPDE was found as
the best binder with an affinity similar to that of the P198
ligand. The data also suggest the sequence AQFDHEAFL
as the 9-mer core region with negative charges in positions
P4 and P6 and a large hydrophobic residue in position P9
that are favorable for interaction with the sDQ2 peptide
binding groove. This sequence contains alanine in position
1, which is not expected to be favorable due to its small
size and the preference that HLA-DQ2 has for bulky
hydrophobic anchor residues at this position (van de Wal et
al. 1996; Vartdal et al. 1996). Notably, peptide binding to
HLA-DQ2 is characterized by contributions from anchor
residues in position 1, 4, 6, 7, and 9 (Kim et al. 2004). This
is in contrast to peptide binding to HLA-DR molecules
which has a dominant contribution of the P1 anchor
(Jardetzky et al. 1990; Stern et al. 1994). Given that the
peptide AQFDHEAFL has optimal anchor residues at
positions P4 (D), P6 (E), and P9 (L), an alanine residue at
P1 with no repulsive effect may well be compatible with
the high affinity binding of this ligand. Moreover, in silico
searching for possible binding registers based on binding
studies with peptide libraries (Jüse et al., unpublished) gave
no better candidates for high affinity HLA-DQ2 ligands
within the 54-mer region. The DCB-45-derived 15-mer
HNAQFDHEAFLGPDE is a good HLA-DQ2 binder, and
we found that it is binding to HLA-DQ2 with a higher
affinity than the HLA-DQ2-α-Ι-gliadin peptide that is an
immunodominant epitope of celiac lesion derived CD4 T
cells. Work parallel to this study (Xia et al. 2007) has
demonstrated that even higher binding affinity than that of
the DCB-45-derived pentadecapeptide as well as high
proteolytic stability are required to obtain HLA-DQ2
blockers that effectively prevent activation of gliadin
reactive T cells. Several chemical modifications that
improve HLA-DQ2 binding affinity and proteolytic resis-
tance would thus be required to make the DCB-45-derived
ligand becoming an effective HLA-DQ2 blocker.
The observations presented in this paper are relevant for
anyone aiming to express MHC class II molecules in S2
cells. DCB-45 is influencing the availability of free and
functional peptide binding site of recombinant sDQ2,
resulting in a decreased peptide binding capacity of the
expressed molecules. Our findings illustrate that de novo
interaction of recombinant MHC class II molecules with
proteins derived from the expression system can occur.
Prior to large scale use in peptide binding studies, such
MHC class II molecules should be carefully characterized
and compared with respect to peptide binding specificity
and capacity to the wild type molecules, which are, e.g.,
purified from Epstein–Barr virus-transformed B lympho-
blastoid cell lines.
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Abstract:
Here we report on a novel peptide library based method for HLA class II binding 
motif identification. The approach is based on water soluble HLA class II molecules 
and soluble dedicated peptide libraries. A high number of different synthetic peptides 
are competing to interact with a limited amount of HLA molecules, giving a selective 
force in the binding. The peptide libraries can be designed so that the sequence length, 
the alignment of binding registers, the numbers and composition of random positions 
are controlled, and also non-natural amino acids can be included. Selected library 
peptides bound to HLA are then isolated by size exclusion chromatography and 
sequenced by tandem mass spectrometry online coupled to liquid chromatography. 
The MS/MS data are subsequently searched against a library defined database using a 
search engine such as Mascot, followed by manual inspection of the results. We used 
two dodecamer and two decamer peptide libraries and HLA-DQ2.5 to test 
possibilities and limits of this method. The selected sequences which we identified in 
the fraction eluted from HLA-DQ2.5 showed a higher average of their predicted 
binding affinity values compared to the original peptide library. The eluted sequences 
fit very well with the previously described HLA-DQ2.5 peptide binding motif. This 
novel method allows the analysis of several thousand synthetic sequences 
concomitantly in a simple water soluble format. 
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1. Introduction 
HLA associations are seen for most autoimmune diseases. HLA-DQ2.5 
(DQA1*0501/DQB1*0201) of the B8-DR3-DQ2 haplotype is associated with 
particularly many diseases, including type 1 diabetes, Addison’s disease, systemic 
lupus erythematosus and celiac disease.1,2,3 Celiac disease is a complex inflammatory 
disorder of the small intestine, and HLA-DQ2.5 exerts a central role in the 
pathogenesis of this disease by presenting gluten peptides to specific CD4+T-cells in 
the intestinal mucosa.4 Over 90% of the celiac disease patients express HLA-
DQ2.5.5,6 For celiac disease, but also other HLA-DQ2.5 associated diseases, specific 
interference with this key molecule can represent a novel treatment strategy. An HLA 
blocker should interfere with the binding of immunogenic peptide(s), but should not 
be recognized by any T cell receptor. So far, the most promising approaches for 
blocking of the HLA-DQ2.5 mediated presentation of gluten derived antigens is the 
use of cyclic and dimeric gluten peptides,7 or the introduction of a large, chemically 
modified side chain into gluten epitopes.8 However, the efficacy of the designed 
blockers for inhibiting T cell activation in vitro is inadequate, and it appears that 
insufficient affinity of the blockers for HLA-DQ2.5 is at least one limitation. 
 
In this study we present a method to identify optimal HLA class II ligands. By 
incubating peptide libraries with several randomized positions with limited amounts 
of HLA molecules, an environment of strong competition is created in which HLA-
DQ2.5 selects for the best binders (Fig. 1). Identification of the selected ligands is 
done by mass spectrometry, and thus also non-natural amino acids can be included in 
the libraries. We here report on the strengths and weaknesses of the method and 
present data on HLA-DQ2.5 ligands and the peptide binding motif of this molecule. 
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2. Results
2.1. Peptide libraries with a single randomized position – libraries A and B 
Peptide libraries with a single randomized position were used to optimize separation 
of HLA-DQ2.5-peptide complexes from unbound peptides and to explore the 
possibilities of this novel method. Due to the low complexity, the libraries could be 
easily analyzed by MALDI-TOF mass spectrometry without the need for LC-based 
peptide separation. In addition, as each peptide sequence is defined by its [M+H]+ 
value, sequence identification of the detected peptides by database searching was not 
required. Notably, for some peptides the isotopic envelopes overlap and the 
contribution of the different peptides to signal intensity was calculated by using their 
theoretical isotopic envelope (supplementary Fig. S1). We used two dodecapeptide 
libraries each carrying a single X position in the anchor positions P1 or P9 (Table 1).  
The mass spectra of library A, which were acquired from the original peptide library 
and from the peptides eluted from HLA-DQ2.5, are shown in Fig. 2. All [M+H]+ 
values calculated from the format of this library were observed in the mass spectrum 
of the original library. For the eluted sample, significant signals (18>x for Y) were 
only obtained for [M+H]+ values which corresponded to sequences with bulky 
hydrophobic amino acids in position P9 (V, L/I, F, Y, W). Library B, carrying the 
randomized position P1, was analyzed by the same method. For the original library, 
[M+H]+ values corresponding to all expected peptide sequences, except the one with 
proline in the X position, were identified. By contrast to library A, the effect of the 
selection by HLA-DQ2.5 was less pronounced for library B as we found signals for 
all 19 peptide sequences in the eluted sample (data not shown). 
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2.2. Peptide library with four dedicated Z positions – library C 
LC-MS/MS analysis of peptide library C on an LTQ-Orbitrap XL mass spectrometer 
resulted in 5059 MS/MS events for the original library (Table 2). A Mascot search of 
these MS/MS events against a library defined database led to the identification of 669 
peptides (Table 2). The RD values for each of the amino acids in the dedicated Z 
positions of these peptides were in the range of 0.5 and 1.5, not far from the expected 
RD value of 1 (Fig. 3A). 
 
LC-MS/MS analysis of the sample after elution from HLA-DQ2.5 resulted in 707 
MS/MS events (Table 2). Mascot reported 81 unique top ranking sequences, however, 
for the majority of these 81 MS/MS events, more than one peptide sequence was 
assigned by a significant score. Therefore, all of these MS/MS events were subjected 
to additional manual data inspection, including examination of their retention times 
and elution profiles, as isobaric peptides can differ slightly in their LC retention times 
(Fig. 4). Additionally, for these 81 MS/MS events, we manually compared the 
observed fragment ions with their theoretical fragmentation patterns. This manual 
data evaluation resulted in the exclusion of 12 sequences and inclusion of 12 
sequences. Thus, 81 unique sequences were identified from library C after selection 
by HLA-DQ2.5 (supplementary Table S1). 
 
Based on these final 81 identified sequences, RD values were calculated for each 
amino acid present in the four dedicated Z positions. These RD values indicated that 
HLA-DQ2.5 favored valine, alanine and glutamate at position P6, glutamate in 
position P7 and P8 and valine, leucine, glutamate, tyrosine, aspartate, methionine, 
phenylalanine and tryptophan at position P9 (Fig. 3B). In contrast, a few amino acids 
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were not detected or present in low amounts in the dedicated Z positions. These were 
glutamine, threonine, asparagine and glycine at position P6, glycine at position P7 and 
glycine, serine and proline at position P9 (Fig. 3B). 
 
For all peptides theoretically present in the original library C, and for the 81 peptides 
identified in the eluted sample, we calculated the sum of the relC values (relC). For 
the eluted peptides the average of these relC values was increased by 1.7 compared 
to the average of the relC values of all peptides of library C (Fig. 5). This finding 
suggests that HLA-DQ2.5 has indeed selected for optimal HLA-DQ2.5 ligands. 
 
2.3. Peptide library with six dedicated Z positions – library D 
LC-MS/MS analysis of peptide library D resulted in 5791 MS/MS events for the 
original library and 1212 MS/MS events for the eluted peptide sample after incubation 
with HLA-DQ2.5 (Table 2). The MS/MS data obtained for the original library were 
subjected to a Mascot search, and we could identify 1985 of the 65350 theoretically 
possible peptide sequences (Table 2). Based on these peptides, we calculated RD 
values for the amino acids in the dedicated Z positions, and found that they varied 
between 0.1 and 3.8 (Fig. 6A).  
 
After peptide selection by HLA-DQ2.5, the obtained MS/MS data were searched by 
Mascot resulting in the identification of 179 unique top ranking peptide sequences. 
All MS/MS events that had more than one peptide sequence assigned by a significant 
score were manually inspected. As only 3% of the theoretical sequences of library D 
were identified in the sample before incubation with HLA-DQ2.5, this manual 
evaluation did not include comparison of retention times and elution profiles but 
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consisted only of comparison of the observed with the theoretical fragmentation 
patterns. This manual data evaluation increased the number of identified sequences to 
261 (Table 2, supplementary Table S2). The average of the relC values of the eluted 
peptides was increased by 3.3 compared to the average of the relC values of all 
peptides present in the original library D (Fig. 5). This suggests an enrichment of 
optimal HLA-DQ2.5 binding peptides from library D also. 
 
As RD values of amino acids in the dedicated positions of the original library D 
showed substantial deviation from 1, there is a likely bias in the RD values calculated 
for the HLA-DQ2.5 selected sample (Fig. 6B). In order to compensate for this bias, 
we calculated adjusted RD values by dividing the RD values obtained for the HLA-
DQ2.5 selected sample by the RD values obtained for the original library (Fig. 6C). 
These adjusted RD values suggest that HLA-DQ2.5 favored phenylalanine and 
tryptophane at position P1; valine, glutamate and leucine at position P4; valine, 
glutamate, proline, alanine and leucine at position P6; glutamate and leucine at 
position P7, glutamate at position P8, and phenylalanine, leucine, tryptophan, tyrosine 
and methionine at position P9 (Fig. 6C). Several amino acids were not detectable or 
present at low abundance at some positions, when the peptide sample selected by 
HLA-DQ2.5 was analyzed. These included proline, valine and glutamate at position 
P1; threonine, glycine, tryptophane and tyrosine at position P4, glutamine at position 
P6; glycine at P7; and glycine, glutamine, serine, valine and glutamate at position P9. 
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3. Discussion and conclusions 
Here we report on a new method for the specific enrichment of peptides with high 
affinity to a HLA class II molecule from complex soluble dedicated peptide libraries. 
This method allows identification of high affinity ligands as well as refined definition 
of peptide binding motifs. 
 
Interfering with antigen presentation by blocking the binding groove of HLA class II 
molecules is a conceivable strategy for the treatment of HLA associated diseases. 
HLA-DQ2.5 is a particular attractive target, as many diseases show associations with 
this HLA molecule.9 Development of HLA-DQ2.5 specific blockers has however so 
far given limited results, and an obvious limitation is the HLA binding affinity of the 
blockers. Thus there is a need for tools that allow the identification of high affinity 
ligands and that allow for testing of compounds incorporating non-natural amino 
acids. Here we present a peptide library based method, that should work equally well 
with natural as well as non-natural amino acids, as the detection is undertaken by 
mass spectrometry. The proof of principle of the method has been established by use 
of natural amino acids and dedicated peptide libraries. 
 
We first analyzed peptide libraries with a single fully randomized X position in the 
anchor positions P1 and P9. By comparing the MALDI-TOF mass spectra of the 
peptide library before incubation with the spectra after elution, we found a specific 
depletion of several peptides. Peptides with bulky hydrophobic amino acids at 
position P9 were favored by HLA-DQ2.5 and were the only sequences observed in 
the eluted sample. At position P1 however, HLA-DQ2.5 was less selective and bound 
all of the 19 tested peptides. Prior studies have shown, that HLA-DQ2.5 both at 
9 
 
positions P9 and P1 prefer amino acids with bulky hydrophobic side chains.10,11 
However, many immunogenic gliadin peptides have the non-bulky amino acid proline 
at position P1, but never in position P9.12,13,14 This suggests that at position P1, a non-
preferred amino acid can be selected, provided all other anchors are optimal. 
 
Next we designed two dedicated peptide libraries with four and six dedicated 
positions (Z). For peptide library C, with four dedicated Z positions, we chose a 
decapeptide library format with four neighboring dedicated Z positions in the C-
terminal part. Notably, the N-terminal anchor positions P1 and P4 were occupied by 
alanine, a non-optimal anchor residue for HLA-DQ2.5. By using this format, we 
sought to solely identify sequences with optimal residues in all of the three anchor 
positions P6, P7 and P9. Each of the dedicated Z positions was composed of 2 to 13 
amino acids, that previously have been demonstrated to be intermediate or good 
residues in the corresponding positions (Fig. 7).15 In peptide library D, two additional 
dedicated Z positions were placed in the two remaining anchor positions, P1 and P4. 
These Z positions were composed of altogether five (at P1) and nine (at P9) amino 
acids, that previously have been demonstrated to be intermediate and good anchor 
residues for these positions (Fig. 7). The two additional Z positions increased the 
complexity of the peptide library by 50-fold compared to library C. In library D, a 
total of 65 000 sequences competed for binding to HLA-DQ2.5. Due to the 
complexity it was necessary to separate peptides in libraries C and D by liquid 
chromatography prior to MS/MS analysis, and for sequence identification a library-
defined database and a search engine (Mascot) was required. 
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The HLA-DQ2.5 selected sequences identified from both the C and D libraries had 
higher average relC values than the peptides each library was composed of. This is 
suggesting that the HLA-DQ2.5 affinity matrix did select for ligands with increased 
affinity in both cases. From library C we identified a panel of 81 peptide ligands 
(Table 2, supplementary Table S1), and we established RD values which designated 
preferred and less preferred anchor residues at the P6, P7 and P9 positions (Fig. 3B). 
Notably, about half of the theoretically possible sequences were identified when 
analyzing the original library C. The approximately equal distribution of amino acids 
in the dedicated positions, argues for a high quality of the peptide libraries used in this 
study. 
 
The data obtained from library D is less informative. There was an uneven 
representation of amino acids in the dedicated positions of the original library which 
was probably introduced during the synthesis of the library, or which is due to a 
random error, introduced when Mascot is searching a database of that high 
complexity. The list of identified peptides from the sample selected by HLA-DQ2.5 
might therefore also be biased. We therefore adjusted the RD values for these selected 
peptides, and these adjusted RD values give some insight into the HLA-DQ2.5 
binding motif.  
 
Our approach can easily be extended to the incorporation of non-natural amino acids 
into the peptide libraries, as the identification of selected ligands is done by tandem 
mass spectrometry. It appears that efficient HLA-DQ2.5 blockers can not solely be 
made of natural amino acids.7 Ongoing research has started exploring high affinity 
binders to HLA-DQ2.5 with both proteinogenic and modified, non-natural amino 
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acids.7,8 Hopefully this work can lead to the development of blockers which show 
sufficient efficacy in vitro and in vivo.  
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4. Experimental
4.1. Soluble HLA-DQ2.5 molecules, expression and purification 
Water soluble HLA-DQ2.5 molecules (DQA1*0501/DQB1*0201) tethered with the 
DQ2--I-gliadin epitope (sDQ2-I) were expressed and purified as described 
before.16 The purity of HLA-DQ2.5 preparations was analyzed by SDS-PAGE. 
Protein concentrations were determined by a BCA protein assay kit (Pierce, Rockford, 
IL, USA). 
 
4.2. Peptide library design 
We tested altogether four peptide libraries based on the same sequence scaffold 
(Table 1). Two dodecapeptide libraries, named A and B, were randomized at one 
position each (position X) which was composed of an equimolar mixture of all natural 
amino acids, except cysteine. These X positions were either placed at anchor position 
P9 (library A) or anchor position P1 (library B) of the HLA-DQ2.5 binding register 
(Table 1). Further, we used two acetylated decapeptide amide libraries with 4 and 6 
dedicated positions with limited variation. In these libraries the dedicated positions 
(positions Z) were composed of an equimolar mixture of 2 to 13 different 
proteinogenic amino acids and placed in several anchor positions and one non-anchor 
position of the HLA-DQ2.5 binding frame (Fig. 1, Table 1). In library C, the Z 
positions were placed in positions P6, P7, P8 and P9, and in library D, the Z positions 
were localized in positions P1, P4, P6, P7, P8 and P9. The amino acids selected for 
the Z positions of the libraries C and D were residues assumed to be intermediate to 
optimal anchors based on their relative competition (relC) values (>1.5) as previously 
established by a scanning peptide library approach (Fig. 7).15 Further, both libraries 
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carried lysine in position P5 and arginine in position P10 to prevent binding of each 
peptide in multiple binding registers. In all other positions alanine was used.  
 
4.3. Peptide library synthesis 
Peptide libraries with one X position were synthesized on Rink amide MBHA-resin 
using Fmoc/HBTU chemistry and a pipetting robot (Syro I, MultiSynTech, Bochum, 
Germany). The randomized X position was coupled by using an equimolar mixture of 
all proteinogenic amino acids except cysteine. Coupling was performed twice using 
equimolar amounts of amino acids and available amino groups. Libraries C and D 
were purchased from EZBiolab (EZBiolab Inc., Carmel, USA). 
 
4.4. Competitive binding conditions 
sDQ2-I molecules were treated with thrombin (0.1 U per 4.6 μg of sDQ2-I) for 2 
hours at room temperature, followed by a treatment with 0.5 μg 4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride. Subsequent, 50 μg peptide 
library and 1.5 μg soluble HLA-DM (a gift from E. Mellins) were added to 8.3 μg 
thrombin-cleaved sDQ2-I in a total volume of 80 μl phosphate buffered saline 
containing 22.5 mM citric acid and 50.5 mM Na2HPO4 (pH 5.3). The sample was 
incubated for 48 hours at 37 ºC. 
 
4.5. Separation of high affinity peptides by size exclusion chromatography 
Library derived peptides bound to sDQ2 were separated from unbound peptides by 
preparative size exclusion chromatography on an Äkta purifier system (Amersham 
Bioscience Corp., Piscataway, NJ, USA) using a Superdex 200 10/300 GL column 
(Amersham Bioscience) and 15 mM phosphate buffered saline as the mobile phase. 
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The sDQ2 containing fraction was concentrated and sDQ2-bound peptides were 
eluted by adjusting to pH 1 with trifluoroacetic acid. The samples were incubated for 
30 min and peptides were purified on a reversed phase (Poros 20 R2, Applied 
Biosystems, Foster City, CA, USA) packed in 20-μl GELoader tips (Eppendorf, 
Hamburg, Germany). Peptides were eluted with 10 μl 99.9% acetonitrile and the 
sample was dried. 
 
4.6. Identification of peptides from libraries with a single X position by MALDI-TOF 
mass spectrometry 
A volume of 1 μl of the eluted peptide samples was applied on a stainless steel 
MALDI target plate and 0.5 μl of 10 g/L -cyano-4-hydroxycinnamic acid in 70% 
acetonitrile/0.1% TFA was added. MALDI-TOF mass spectra were acquired on an 
Ultraflex II instrument (Bruker Daltonics, Bremen, Germany) and peptide sequences 
were identified manually. For all peptides with an overlapping isotopic envelope, the 
theoretical isotopic distribution was taken into consideration. 
 
4.7. LC-MS/MS analysis of samples from dedicated libraries 
The dried peptide samples were dissolved in 0.1% formic acid and analyzed by 
nanoLC-MS/MS using an EASY nLC system (Proxeon A/S, Odense, Denmark) 
coupled to a LTQ-Orbitrap XL mass spectrometer (ThermoScientific, Bremen, 
Germany) equipped with a nano-electrospray ion source. The peptides were separated 
on a 100 micron ID capillary column 18 cm length, packed with Reprosil C18, 3 
micron. The instrument was set to a linear gradient of 0-34% B for 50 minutes 
(solvent B was 95% acetonitrile), the threshold for fragmentation was set to 15.000 
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and the range was 300-1800. Of the original library samples, 0.4 μg were analyzed by 
using the same settings. 
 
4.8. Peptide identification after analysis of samples from dedicated libraries 
Obtained LC-MS/MS data were extracted from the Orbitrap raw files using the 
Proteome Discoverer software (Thermo Fisher Scientific Inc., Waltham, MA, USA) 
with default settings and searched against a library defined database using Proteome 
Discoverer and the Mascot search engine (Matrixscience Ltd, Boston, MA, USA). 
The following settings were selected: amidated C-terminus and acetylated N-terminus 
as fixed modifications, Arg-C as the enzyme, no missed cleavages, peptide mass 
tolerance of 10 ppm, and fragment ion mass tolerance of 0.6 Da. Search results for the 
original library and for the peptide sample selected by HLA-DQ2.5 were copied to an 
Excel spreadsheet giving information on the peptide sequences reported for each 
MS/MS event, together with their ion scores, rank order and retention times. Due to 
the format of the library, Mascot assigned several isobaric peptides with high scores 
for most of the MS/MS events. As these isobaric peptides share many of their 
fragment ion masses, the exact sequence of a selected parent ion can often only be 
differentiated on the basis of one or a few y- and/or b-fragments. If more than one hit 
was reported by Mascot for a given MS/MS event in the eluted samples, manual data 
inspection was performed. For both dedicated libraries, the theoretical fragmentation 
pattern of all hits reported by Mascot for a particular MS/MS event were compared to 
the fragments observed in the acquired MS/MS spectrum. For library C, the retention 
times and elution profiles for all isobaric peptide sequences reported for an MS/MS 
event were additionally compared with the retention times and elution profiles of all 
of the isobaric peptides in the sample of the original peptide library. For that reason, 
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retention times for the analysis of the original and selected library C were aligned 
using the software POSTMan.17 By this manual data inspection, several top ranking 
hits were excluded as false positive hits whereas other hits were included which 
originally were not assigned by top scores in the Mascot search. 
 
4.9. Analysis of amino acid preference at given positions
Relative distribution (RD) values, given as the frequency of an amino acid at a 
dedicated Z position multiplied by the total number of amino acids represented at the 
same position, were calculated to visualize amino acid preference. At a given 
position, favored amino acids have RD values larger than one, and non-favored amino 
acids have RD values smaller than 1. 
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Table 1 
 
Peptide libraries used in this study. Libraries A and B carry each a single and fully 
randomized X position which is composed of an equimolar mixture of 19 
proteinogenic amino acids (excluding cysteine). Libraries C and D represent 
dedicated peptide libraries with four and six dedicated Z positions whose composition 
are given below. 
 
  peptide binding register  [sequences] 
  1 2 3 4 5 6 7 8 9   
Library A GG F A P E K E E P X R-NH2 19 
Library B GG X A P E K E E P F R-NH2 19 
Library C Ac A A A A K Z Z Z Z R-NH2 1430 
Library D Ac Z A A Z K Z Z Z Z R-NH2 64 350 
 
Amino acid composition in the Z positions of dedicated libraries C and D: 
Z in position 1: P, V, E, W, F 
Z in position 4: P, V, T, G, W, L, Y, N, E 
Z in position 6: Q, T, N, Y, F, V, G, L, A, P, E 
Z in position 7: G, L, F, A, E 
Z in position 8: P, E 
Z in position 9: G, Q, A, S, V, P, L, E, Y, D, M, F, W 
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Table 2 
 
Number of MS/MS events and identified peptides in experiments with libraries C and 
D. 
 
 Library C Library D
Theoretical sequences 1430 64 350 
MS/MS events acquired before incubation 5059 5791 
MS/MS events acquired in the eluted sample 707 1212 
Sequences identified before incubation 669 1985 
Sequences identified in the eluted sample 81 261 
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Figure legends 
 
Fig. 1 
Schematic representation of peptide library D registering into the peptide binding 
groove of HLA-DQ2.5. Five of the six dedicated Z positions interact with the five 
pockets in the groove and one is bridging a ridge in position P8. The positively 
charged amino acid lysine is placed in the non-anchor position P5. 
 
Fig. 2 
MALDI-TOF mass spectrum of the original library A (top) and of the sample 
obtained after incubation of HLA-DQ2.5 with library A and peptide elution (bottom). 
Signals are assigned by the amino acid in the randomized position P9 of the identified 
peptide sequence. 
 
Fig. 3 
Relative distribution (RD) of amino acids present in the dedicated positions of peptide 
library C before incubation (A) and after elution (B). 
 
Fig. 4 
LC-MS map of library C before incubation with HLA-DQ2.5 (left panels) and after 
elution from HLA-DQ2.5 (right panels). The upper panels show the elution profiles in 
the region m/z 425-725 and with retention times from 41 min to 73 min. The lower 
panels present an enlarged 3D view of the rectangular boxes included in the upper 
panels. Before incubation with HLA-DQ2.5, the lower panel shows three peptides 
with slightly different retention times (observed as doubly charged ions). The peptides 
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eluting at 50.1 min and 51.6 min are isobaric with m/z 589.9 and MS/MS data 
allowed identifying their sequences as AAAAKEEEYR and AAAAKYEEER, 
respectively. After incubation with HLA-DQ2.5 only one peptide was observed at an 
aligned retention time of 50.4 min which was identified as AAAAKEEEYR. Images 
were created with MSight version 2.A.6 and aligned retention times were calculated 
using POSTMan. 
 
Fig. 5 
The range of relC values for all peptides present in library C and library D. The 
average of relC values of the original library (**) and of the peptides eluted from 
HLA-DQ2.5 (*) are given. 
 
Fig. 6 
Relative distribution (RD) of amino acids present in the dedicated positions of peptide 
library D before incubation (A) and after elution (B). In order to compensate for a 
potential bias in these data, RD values given in B were divided by RD values given in 
A resulting in adjusted RD values (C). 
 
Fig. 7 
The amino acids in the dedicated positions P1, P4, P6, P7, P8, and P9 in library C and 
D were chosen based on their relative competition values (relC).15 Unfavorable amino 
acids have low relC values; favorable amino acids have high relC values. Residues 
included in dedicated positions of library C and D are indicated in gray. In each 
dedicated position, mainly intermediate and good residues in the corresponding 
position with a relC value greater 1.5 were included (except L in position P7 and P in 
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position 8). The most abundant residues identified in the peptides eluted from HLA-
DQ2.5 after incubation are marked with stars (library C = *, library D = **). By 
comparing RD values of the eluted sample of library D with the RD values of the 
sample before incubation, some additional amino acids are more abundant in the 
eluted sample then before incubation. These amino acids are labeled with (**). In 
library C, tryptophan (W) in position P9 is less abundant in the eluted sample then in 
the sample before incubation (*).
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Fig. 3 
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Fig. 4 
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